Chemed (CHE) 10-K 2007 FY Annual report

Exhibit 13

Financial Review

Contents

Report of Independent Registered Public Accounting Firm		2
Consolidated Statement of Income		3
Consolidated Balance Sheet		4
Consolidated Statement of Cash Flows		5
Consolidated Statement of Changes in Stockholders’ Equity		6
Notes to Consolidated Financial Statements		7
Unaudited Summary of Quarterly Results		35
Selected Financial Data		37
Management’s Discussion and Analysis of Financial Conditions and Results of Operations		38
Officers’ and Directors’ Listing and Corporate Information	IBC

MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

          The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting, as that term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and disposition of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorization of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

          Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

          The Company’s management, including the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller, has conducted an evaluation of the effectiveness of its internal control over financial reporting as of December 31, 2007, based on the framework established inInternal Control—Integrated Frameworkissued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on this evaluation, management concluded that internal control over financial reporting was effective as of December 31, 2007, based on criteria inInternal Control—Integrated Frameworkissued by COSO.

          PricewaterhouseCoopers LLP, our independent registered public accounting firm, has audited the effectiveness of the Company’s internal control over financial reporting as of December 31, 2007, as stated in their report which appears on page 2.

1

Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors of Chemed Corporation

In our opinion, the accompanying consolidated balance sheet and the related consolidated statement of income, cash flows and changes in stockholders’ equity present fairly, in all material respects, the financial position of Chemed Corporation and its subsidiaries at December 31, 2007 and 2006, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2007 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2007, based on criteria established inInternal Control — Integrated Frameworkissued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company’s management is responsible for these financial statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express opinions on these financial statements and on the Company’s internal control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

As discussed in Note 1 to the financial statements, effective January 1, 2006 the Company changed its method of accounting for share-based compensation.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ PricewaterhouseCoopers LLP

Cincinnati, Ohio
February 28, 2008

2

CONSOLIDATED STATEMENT OF INCOME

Chemed Corporation and Subsidiary Companies

(in thousands, except per share data)
For the Years Ended December 31,	2007			2006			2005
Continuing Operations
Service revenues and sales	$	1,100,058		$	1,018,587		$	915,970
Cost of services provided and goods sold (excluding depreciation)		767,066			730,123			644,476
Selling, general and administrative expenses		184,060			161,183			157,262
Depreciation		20,118			16,775			16,150
Amortization		5,270			5,255			4,922
Other operating expenses—net (Note 6)		789			272			16,391
Total costs and expenses		977,303			913,608			839,201
Income from operations		122,755			104,979			76,769
Interest expense		(11,244	)		(17,468	)		(21,264	)
Loss on extinguishment of debt (Note 2)		(13,798	)		(430	)		(3,971	)
Loss from impairment of investment		—			(1,445	)		—
Other income—net (Note 9)		4,125			4,648			3,122
Income before income taxes		101,838			90,284			54,656
Income taxes (Note 10)		(39,063	)		(32,562	)		(18,428	)
Income from continuing operations		62,775			57,722			36,228
Discontinued Operations, Net of Income Taxes (Note 7)		1,201			(7,071	)		(411	)
Net Income	$	63,976		$	50,651		$	35,817
Earnings Per Share (Note 17)
Income from continuing operations	$	2.56		$	2.21		$	1.42
Net Income	$	2.61		$	1.94		$	1.40
Diluted Earnings Per Share (Note 17)
Income from continuing operations	$	2.50		$	2.16		$	1.38
Net Income	$	2.55		$	1.90		$	1.36
Average Number of Shares Outstanding (Notes 17)
Earnings per share		24,520			26,118			25,552
Diluted earnings per share		25,077			26,669			26,299

The Notes to Consolidated Financial Statements are integral parts of this statement.

3

CONSOLIDATED BALANCE SHEET

Chemed Corporation and Subsidiary Companies

(in thousands, except shares and per share data)
December 31,	2007			2006
Assets
Current assets
Cash and cash equivalents (Note 11)	$	4,988		$	29,274
Accounts receivable less allowances of $9,746 (2006 - $10,180)		103,113			93,086
Inventories		6,596			6,578
Current deferred income taxes (Note 10)		14,212			17,789
Current assets of discontinued operations (Note 7)		—			5,418
Prepaid expenses and other current assets		10,496			9,968
Total current assets		139,405			162,113
Investments of deferred compensation plans held in trust (Note 14)		29,417			25,713
Notes receivable (Notes 7 and 16)		9,701			14,701
Properties and equipment, at cost, less accumulated depreciation (Note 12)		74,513			70,140
Identifiable intangible assets less accumulated amortization of $17,245 (2006 - $13,201) (Note 5)		65,177			69,215
Goodwill (Note 5)		438,689			435,050
Noncurrent assets of discontinued operations (Note 7)		—			287
Other assets		15,411			16,068
Total Assets	$	772,313		$	793,287
Liabilities
Current liabilities
Accounts payable	$	48,111		$	49,744
Current portion of long-term debt (Note 2)		10,162			209
Income taxes (Note 10)		4,221			6,765
Accrued insurance		36,337			38,457
Accrued compensation		40,072			35,990
Current liabilities of discontinued operations (Note 7)		—			12,215
Other current liabilities (Note 13)		13,929			22,684
Total current liabilities		152,832			166,064
Deferred income taxes (Note 10)		5,802			26,301
Long-term debt (Note 2)		214,669			150,331
Deferred compensation liabilities (Note 14)		29,149			25,514
Other liabilities		5,512			3,716
Commitments and contingencies (Notes 15, 19 and 20)
Total Liabilities		407,964			371,926
Stockholders’ Equity
Capital stock — authorized 80,000,000 shares $1 par; issued 29,260,791 shares (2006 - 28,849,918 shares)		29,261			28,850
Paid-in capital		267,312			252,639
Retained earnings		278,336			215,517
Treasury stock - 5,299,056 shares (2006 - 3,023,635 shares), at cost		(213,041	)		(78,064	)
Deferred compensation payable in Company stock (Note 14)		2,481			2,419
Total Stockholders’ Equity		364,349			421,361
Total Liabilities and Stockholders’ Equity	$	772,313		$	793,287

The Notes to Consolidated Financial Statements are integral parts of this statement.

4

CONSOLIDATED STATEMENT OF CASH FLOWS

Chemed Corporation and Subsidiary Companies

(in thousands)
For the Years Ended December 31,	2007			2006			2005
Cash Flows from Operating Activities
Net income	$	63,976		$	50,651		$	35,817
Adjustments to reconcile net income to net cash provided by operations:
Depreciation and amortization		25,388			22,030			21,072
Provision for uncollectible accounts receivable		8,373			8,169			7,126
Write-off unamortized debt issuance costs		7,235			430			2,871
Noncash portion of long-term incentive compensation		6,154			—			4,813
Provision for deferred income taxes (Note 10)		8,113			7,408			(5,055	)
Discontinued operations (Note 7)		(1,201	)		7,071			411
Amortization of debt issuance costs		1,186			1,774			1,834
Loss on impairment of investment		—			1,445			—
Changes in operating assets and liabilities, excluding amounts acquired in business combinations:
Increase in accounts receivable		(18,416	)		(12,527	)		(34,145	)
Decrease/(increase) in inventories		(18	)		(78	)		520
Decrease/(increase) in prepaid expenses and other current assets		(549	)		(2,188	)		76
Increase/(decrease) in accounts payable and other current liabilities		(8,299	)		(13,017	)		32,431
Increase in income taxes		6,321			18,726			15,359
Increase in other assets		(3,655	)		(722	)		(2,003	)
Increase/(decrease) in other liabilities		4,426			3,788			(1,146	)
Excess tax benefit on share-based compensation		(3,091	)		(5,600	)		—
Noncash expense of internally financed ESOPs		—			—			1,060
Other sources		3,641			2,109			912
Net cash provided by continuing operations		99,584			89,469			81,953
Net cash provided/(used) by discontinued operations (Note 7)		—			9,120			(1,940	)
Net cash provided by operating activities		99,584			98,589			80,013
Cash Flows from Investing Activities
Capital expenditures		(26,640	)		(21,987	)		(25,734	)
Net uses from sale of discontinued operations (Note 7)		(5,402	)		(922	)		(9,367	)
Proceeds from sales of property and equipment		3,104			347			157
Business combinations, net of cash acquired (Note 8)		(1,079	)		(4,145	)		(6,165	)
Investing activities of discontinued operations (Note 7)		—			(260	)		(239	)
Other uses		(1,701	)		(765	)		(394	)
Net cash used by investing activities		(31,718	)		(27,732	)		(41,742	)
Cash Flows from Financing Activities
Proceeds from issuance of long-term debt (Note 2)		300,000			—			85,000
Repayment of long-term debt (Note 2)		(225,709	)		(84,563	)		(141,592	)
Purchases of treasury stock (Note 22)		(131,704	)		(19,885	)		(7,401	)
Purchase of note hedges (Note 2)		(55,100	)		—			—
Proceeds from issuance of warrants (Note 2)		27,614			—			—
Debt issuance costs		(6,949	)		(154	)		(1,755	)
Dividends paid		(5,888	)		(6,322	)		(6,172	)
Excess tax benefit on share-based compensation		3,091			5,600			—
Proceeds from exercise of stock options (Note 3)		2,467			3,861			12,327
Change in cash overdraft payable		(919	)		2,571			6,752
Other sources		945			176			255
Net cash used by financing activities		(92,152	)		(98,716	)		(52,586	)
Decrease in cash and cash equivalents		(24,286	)		(27,859	)		(14,315	)
Cash and cash equivalents at beginning of year		29,274			57,133			71,448
Cash and cash equivalents at end of year	$	4,988		$	29,274		$	57,133

The Notes to Consolidated Financial Statements are integral parts of this statement.

5

CONSOLIDATED STATEMENT OF CHANGES
IN STOCKHOLDERS’ EQUITY

Chemed Corporation and Subsidiary Companies

												Deferred
												Compensation		Notes
									Treasury			Payable in		Receivable
	Capital		Paid-in			Retained			Stock-			Company		for
(in thousands, except per share data)	Stock		Capital			Earnings			at Cost			Stock		Shares Sold			Total
Balance at December 31, 2004	$	13,491	$	209,101		$	141,542		$	(33,873	)	$	2,375	$	(544	)	$	332,092
Net income		—		—			35,817			—			—		—			35,817
Dividends paid ($.24 per share)		—		—			(6,172	)		—			—		—			(6,172	)
Stock awards and exercise of stock options (Note 3)		1,028		38,383			—			(18,204	)		—		—			21,207
Impact of common share split		13,855		(13,855	)		—			—			—		—			—
Purchases of treasury stock		—		1,060			—			(41	)		—		—			1,019
Decrease in notes receivable		—		—			—			(9	)		—		(5	)		(14	)
Other		—		221			1			—			4		—			226
Balance at December 31, 2005		28,374		234,910			171,188			(52,127	)		2,379		(549	)		384,175
Net income		—		—			50,651			—			—		—			50,651
Dividends paid ($.24 per share)		—		—			(6,322	)		—			—		—			(6,322	)
Stock awards and exercise of stock options (Note 3)		476		17,663			—			(9,840	)		—		—			8,299
Purchases of treasury stock		—		—			—			(15,612	)		—		—			(15,612	)
Decrease in notes receivable		—		—			—			(485	)		—		549			64
Other		—		66			—			—			40		—			106
Balance at December 31, 2006		28,850		252,639			215,517			(78,064	)		2,419		—			421,361
Cumulative effect of change in accounting principle as of January 1, 2007 (Notes 1 and 10)		—		—			4,731			—			—		—			4,731
Net income		—		—			63,976			—			—		—			63,976
Dividends paid ($.24 per share)		—		—			(5,888	)		—			—		—			(5,888	)
Stock awards and exercise of stock options (Note 3)		411		21,141			—			(7,032	)		—		—			14,520
Purchases of treasury stock (Note 22)		—		—			—			(127,881	)		—		—			(127,881	)
Purchase of note hedges (Note 2)		—		(54,894	)		—			—			—		—			(54,894	)
Deferred tax benefit of purchased note hedges (Note 2)		—		20,036			—			—			—		—			20,036
Proceeds from issuance of warrants (Note 2)		—		27,614			—			—			—		—			27,614
Other		—		776			—			(64	)		62		—			774
Balance at December 31, 2007	$	29,261	$	267,312		$	278,336		$	(213,041	)	$	2,481	$	—		$	364,349

The Notes to Consolidated Financial Statements are integral parts of this statement.

6

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Chemed Corporation and Subsidiary Companies

1. Summary of Significant Accounting Policies

NATURE OF OPERATIONS

     We operate through our two wholly owned subsidiaries, VITAS Healthcare Corporation (“VITAS”) and Roto-Rooter Group, Inc. (“Roto-Rooter”). VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its team of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter is focused on providing plumbing and drain cleaning services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

PRINCIPLES OF CONSOLIDATION

     The consolidated financial statements include the accounts of Chemed Corporation and its wholly owned subsidiaries. All significant intercompany transactions have been eliminated.

     We have analyzed the provisions of Financial Accounting Standards Board (“FASB”) Interpretation No. 46R “Consolidation of Variable Interest Entities—an interpretation of Accounting Research Bulletin No. 51 (revised)” (“FIN 46R”) relative to contractual relationships with our Roto-Rooter independent contractors and franchisees. FIN 46R requires the primary beneficiary of a Variable Interest Entity (“VIE”) to consolidate the accounts of the VIE. We have evaluated the relationships with our independent contractors and franchisees based upon guidance provided in FIN 46R and have concluded that certain of the independent contractors may be VIEs. Based on our evaluation, the franchisees are not VIEs. We believe consolidation, if required, of the accounts of any independent contractor for which we might be the primary beneficiary would not materially impact our financial position or results of operations.

CASH EQUIVALENTS

     Cash equivalents comprise short-term, highly liquid investments that have been purchased within three months of their dates of maturity.

ACCOUNTS AND LOANS RECEIVABLE AND CONCENTRATION OF RISK

     Accounts and loans receivable are recorded at the principal balance outstanding less estimated allowances for uncollectible accounts. For the Roto-Rooter segment, allowances for trade accounts receivable are generally provided for accounts more than 90 days past due, although collection efforts continue beyond that time. Due to the small number of loans receivable outstanding, allowances for loan losses are determined on a case-by-case basis. For the VITAS segment, allowances for patient accounts receivable are generally provided on accounts more than 240 days old plus an appropriate percentage of accounts not yet 240 days old. Final write-off of overdue accounts or loans receivable is made when all reasonable collection efforts have been made and payment is not forthcoming. We closely monitor our receivables and periodically review procedures for granting credit to attempt to hold losses to a minimum.

     As of December 31, 2007 and 2006, approximately 63% and 62%, respectively, of VITAS’ total accounts receivable balance were due from Medicare and 28% and 30%, respectively, of VITAS’ total accounts receivable balance were due from various state Medicaid programs. Combined accounts receivable from Medicare and Medicaid represent 80% of the net accounts receivable in the accompanying consolidated balance sheet as of December 31, 2007. We closely monitor our programs to ensure compliance with Medicare and Medicaid regulations.

INVENTORIES

     Substantially all of the inventories are either general merchandise or finished goods. Inventories are stated at the lower of cost or market. For determining the value of inventories, cost methods that reasonably approximate the first-in, first-out (“FIFO”) method are used.

OTHER INVESTMENTS

     To the extent that we hold any, investments are reviewed periodically for impairment based on available market and financial data. If the market value or net realizable value of the investment is less than our cost and the decline is determined to be other than temporary, a write-down to fair value is made and a realized loss is recorded in the statement of income. In calculating realized gains and losses on the sales of investments, the specific-identification method is used to determine the cost of investments sold.

7

Chemed Corporation and Subsidiary Companies

DEPRECIATION AND PROPERTIES AND EQUIPMENT

     Depreciation of properties and equipment is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the lesser of the remaining lease terms (excluding option terms) or their useful lives. Expenditures for maintenance, repairs, renewals and betterments that do not materially prolong the useful lives of the assets are expensed as incurred. The cost of property retired or sold and the related accumulated depreciation are removed from the accounts, and the resulting gain or loss is reflected currently in income.

     Expenditures for major software purchases and software developed for internal use are capitalized and depreciated using the straight-line method over the estimated useful lives of the assets. For software developed for internal use, external direct costs for materials and services and certain internal payroll and related fringe benefit costs are capitalized in accordance with Statement of Position 98-1, “Accounting for the Costs of Computer Software Developed or Obtained for Internal Use.”

     The weighted average lives of our property and equipment at December 31, 2007, were:

Buildings	12.8		yrs.
Transportation equipment		5.9
Machinery and equipment		5.8
Computer software		4.3
Furniture and fixtures		4.8

GOODWILL AND INTANGIBLE ASSETS

     Identifiable, definite-lived intangible assets arise from purchase business combinations and are amortized using either an accelerated method or the straight-line method over the estimated useful lives of the assets. The selection of an amortization method is based on which method best reflects the economic pattern of usage of the asset. The VITAS trade name is considered to have an indefinite life. Goodwill and the VITAS trade name are tested at least annually for impairment.

     The weighted average lives of our identifiable, definite-lived intangible assets at December 31, 2007, were:

Covenants not to compete	6.3		yrs.
Referral networks		10.0
Customer lists		13.3

LONG-LIVED ASSETS

     If we believe a triggering event may have occurred that indicates a possible impairment of our long-lived assets, we perform an estimate and valuation of the future benefits of our long-lived assets (other than goodwill and the VITAS trade name) based on key financial indicators. If the projected undiscounted cash flows of a major business unit indicate that property and equipment or identifiable, definite-lived intangible assets have been impaired, a write-down to fair value is made.

OTHER ASSETS

     Debt issuance costs are included in other assets and are amortized using the effective interest method over the life of the debt.

     We capitalize the direct costs of obtaining licenses to operate hospice programs subject to a minimum capitalization threshold. These costs are amortized over the life of the license using the straight-line method. Certain licenses are granted without an expiration and thus, we believe them to be indefinite-lived assets subject to impairment testing on at least an annual basis.

REVENUE RECOGNITION

     Both the VITAS segment and Roto-Rooter segment recognize service revenues and sales when the earnings process has been completed. Generally, this occurs when services are provided or products are delivered. Sales of Roto-Rooter products, including drain cleaning machines and drain cleaning solution, comprise less than 2% of our total service revenues and sales for each of the three years in the period ended December 31, 2007.

     VITAS recognizes revenue at the estimated realizable amount due from third-party payers, which are primarily Medicare and Medicaid. Payers may deny payment for services in whole or in part on the basis that such services are not

8

Chemed Corporation and Subsidiary Companies

eligible for coverage and do not qualify for reimbursement. We estimate denials each period and make adequate provision in the financial statements. The estimate of denials is based on historical trends and known circumstances and does not vary materially from period to period on an aggregate basis. Medicare billings are subject to certain limitations, as described below.

     VITAS is subject to certain limitations on Medicare payments for services. Specifically, if the number of inpatient care days any hospice program provides to Medicare beneficiaries exceeds 20% of the total days of hospice care such program provided to all Medicare patients for an annual period beginning September 28, the days in excess of the 20% figure may be reimbursed only at the routine homecare rate. None of VITAS’ hospice programs exceeded the payment limits on inpatient services in 2007, 2006 or 2005.

     VITAS is also subject to a Medicare annual per-beneficiary cap (“Medicare Cap”). Compliance with the Medicare Cap is measured by comparing the total Medicare payments received under a Medicare provider number with respect to services provided to all Medicare hospice care beneficiaries in the program or programs covered by that Medicare provider number between November 1 of each year and October 31 of the following year with the product of the per-beneficiary cap amount and the number of Medicare beneficiaries electing hospice care for the first time from that hospice program or programs from September 28 through September 27 of the following year.

     We actively monitor each of our hospice programs, by provider number, as to their specific admission, discharge rate and median length of stay data in an attempt to determine whether revenues are likely to exceed the annual per-beneficiary Medicare cap. Should we determine that revenues for a program are likely to exceed the Medicare Cap based on projected trends, we attempt to institute corrective action to change the patient mix or to increase patient admissions. However, should we project our corrective action will not prevent that program from exceeding its Medicare Cap, we estimate the amount of revenue recognized during the period that will require repayment to the Federal government under the Medicare Cap and record the amount as a reduction to service revenue.

     Our estimate of the Medicare Cap liability is particularly sensitive to allocations made by our fiscal intermediary relative to patient transfers between hospices. We are allocated a percentage of the Medicare Cap based on the days a patient spent in our care as compared to the total days a patient spent in hospice care. The allocation for patient transfers cannot be determined until a patient dies. As the number of days a patient spends in hospice is based on a future event, this allocation process may take several years. Therefore, we use only first-time Medicare admissions in our estimate of the Medicare Cap billing limitation. This method assumes that credit received for patients who transfer into our program will be offset by credit lost from patients who transfer out of our program. The amount we record is our best estimate of the liability as of the date of the financial statements but could change as more patient information becomes available.

     During the years ended December 31, 2007 and 2006, we recorded pretax charges in continuing operations of $242,000 and $3.9 million, respectively, for the estimated Medicare cap liability. The amount recorded in 2007 relates primarily to retroactive billings for prior-measurement periods due to patients who transferred between multiple hospice providers.

SALES TAX

     The Roto-Rooter segment collects sales tax from customers when required by state and federal laws. We record the amount of sales tax collected net in the accompanying consolidated statement of income.

GUARANTEES

     In the normal course of business, we enter into various guarantees and indemnifications in our relationships with customers and others. These arrangements include guarantees of services for periods ranging from one day to one year and product satisfaction guarantees. Our experience indicates guarantees and indemnifications do not materially impact our financial condition or results of operations. Based on our experience, no liability for guarantees has been recorded as of December 31, 2007 or 2006.

OPERATING EXPENSES

     Cost of services provided and goods sold (excluding depreciation) includes salaries, wages and benefits of service providers and field personnel, material costs, medical supplies and equipment, pharmaceuticals, insurance costs, service vehicle costs and other expenses directly related to providing service revenues or generating sales. Selling, general and administrative expenses include salaries, wages, stock option expense and benefits of selling, marketing and administrative employees, advertising expenses, communications and branch telephone expenses, office rent and operating costs, legal, banking and professional fees and other administrative costs.

9

Chemed Corporation and Subsidiary Companies

ADVERTISING

     We expense the production costs of advertising the first time the advertising takes place. The costs of yellow page listings are expensed when the directories are placed in circulation. These directories are generally in circulation for approximately one year, at which point they are replaced by the publisher with a new directory. We generally pay for directory placement assuming it is in circulation for one year. If the directory is in circulation for less than or greater than one year, we receive a credit or additional billing, as necessary. We do not control the timing of when a new directory is placed in circulation. Other advertising costs are expensed as incurred. Advertising expense in continuing operations for the year ended December 31, 2007, was $26.0 million (2006 — $23.3 million; 2005 — $21.2 million).

COMPUTATION OF EARNINGS PER SHARE

     Earnings per share are computed using the weighted average number of shares of capital stock outstanding. Diluted earnings per share reflect the dilutive impact of our outstanding stock options and nonvested stock awards. Stock options whose exercise price is greater than the average market price of our stock are excluded from the computation of diluted earnings per share.

     Diluted earnings per share may be impacted in future periods as the result of the issuance of our $200 million Notes and related purchased call options and sold warrants, as described in Note 2. Under Emerging Issues Task Force (“EITF”) 04-8, “The Effect of Contingently Convertible Instruments on Diluted Earnings per Share” and EITF 90-19, “Convertible Bonds with Issuer Option to Settle for Cash Upon Conversion” we will not include any shares related to the Notes in our calculation of diluted earnings per share until our average stock price for a quarter exceeds the conversion price of $80.73. We would then include in our diluted earnings per share calculation those shares issuable using the treasury stock method. The amount of shares issuable is based upon the amount by which the average stock price for the quarter exceeds the conversion price. The purchased call option does not impact the calculation of diluted earnings per share, as it is always anti-dilutive. The sold warrants become dilutive when our average stock price for a quarter exceeds the strike price of the warrant.

     The following table provides examples of how changes in our stock price impact the number of shares that would be included in our diluted earnings per share calculation. It also shows the impact on the number of shares issuable upon conversion of the Notes and settlement of the purchased call options and sold warrants:

	Shares				Total Treasury		Shares Due			Incremental
	Underlying 1.875%				Method		to the Company			Shares Issued by
Share	Convertible		Warrant		Incremental		under Notes			the Company
Price	Notes		Shares		Shares (a)		Hedges			upon Conversion (b)
$80.73		—		—		—		—			—
$90.73		273,061		—		273,061		(273,061	)		—
$100.73		491,905		—		491,905		(491,905	)		—
$110.73		671,222		118,359		789,581		(671,222	)		118,359
$120.73		820,833		313,764		1,134,597		(820,833	)		313,764
$130.73		947,556		479,274		1,426,830		(947,556	)		479,274

(a)	Represents the number of incremental shares that must be included in the calculation of fully diluted shares under U.S. GAAP.
(b)	Represents the number of incremental shares to be issued by the Company upon conversion of the 1.875% Convertible Notes, assuming concurrent settlement of the note hedges and warrants.

STOCK-BASED COMPENSATION PLANS

     Effective January 1, 2006, we adopted the provisions of Statement of Financial Accounting Standards No. 123, revised (“SFAS 123(R)”) which establishes accounting for stock-based compensation for employees. Under SFAS 123(R), stock-based compensation cost is measured at the grant date, based on the fair value of the award and recognized as expense over the employee’s requisite service period on a straight-line basis. We previously applied Accounting Principles Board Opinion No. 25 and provided the pro-forma disclosures required by Statement of Financial Accounting Standards No. 123. We elected to adopt the modified prospective transition method as provided by SFAS 123(R). Accordingly, we have not restated previously reported financial statement amounts. Other than certain reclassifications, there was no material impact on our financial position, results of operations or cash flows as a result of the adoption of SFAS 123(R) in 2006.

10

Chemed Corporation and Subsidiary Companies

INSURANCE ACCRUALS

     For our Roto-Rooter segment and Corporate Office, we self-insure for all casualty insurance claims (workers’ compensation, auto liability and general liability). As a result, we closely monitor and frequently evaluate our historical claims experience to estimate the appropriate level of accrual for self-insured claims. Our third-party administrator (“TPA”) processes and reviews claims on a monthly basis. Currently, our exposure on any single claim is capped at $500,000. In developing our estimates, we accumulate historical claims data for the previous 10 years to calculate loss development factors (“LDF”) by insurance coverage type. LDFs are applied to known claims to estimate the ultimate potential liability for known and unknown claims for each open policy year. LDFs are updated annually. Because this methodology relies heavily on historical claims data, the key risk is whether the historical claims are an accurate predictor of future claims exposure. The risk also exists that certain claims have been incurred and not reported on a timely basis. To mitigate these risks, in conjunction with our TPA, we closely monitor claims to ensure timely accumulation of data and compare claims trends with the industry experience of our TPA.

     For the VITAS segment, we self-insure for workers’ compensation claims. Currently, VITAS’ exposure on any single claim is capped at $500,000. For VITAS’ self-insurance accruals for workers’ compensation, the valuation methods used are similar to those used internally for our other business units.

     Our casualty insurance liabilities are recorded gross before any estimated recovery for amounts exceeding our stop loss limits. Estimated recoveries from insurance carriers are recorded as accounts receivable.

TAXES ON INCOME

     Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amount of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in our opinion, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in laws and rates on the date of enactment.

     We are subject to income taxes in Canada, U.S. Federal and most state jurisdictions. Significant judgment is required to determine our provision for income taxes. On January 1, 2007, we adopted FASB Interpretation No. 48 (FIN 48), “Accounting for Uncertainty in Income Taxes — an Interpretation of FASB Statement 109,” which prescribes a comprehensive model to recognize, measure, present and disclose in financial statements uncertain tax positions taken or expected to be taken on a tax return. Upon adoption of FIN 48, our financial statements reflect expected future tax consequences of such uncertain positions assuming the taxing authorities’ full knowledge of the position and all relevant facts. FIN 48 also revises disclosure requirements and introduces an annual, tabular roll-forward of the unrecognized tax benefits. The cumulative effect upon adoption of FIN 48 was to reduce our accrual for uncertain tax positions by approximately $4.7 million, which has been recorded in retained earnings as of January 1, 2007, in the accompanying consolidated balance sheet.

ESTIMATES

     The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Disclosures of aftertax expenses and adjustments are based on estimates of the effective income tax rates for the applicable segments.

RECENT ACCOUNTING STATEMENTS

     In December 2007, the FASB issued Statement No. 141(R) “Business Combinations (revised 2007)” (“SFAS 141(R)”), which changes certain aspects of the accounting for business combinations. This Statement retains the fundamental requirements in Statement No. 141 that the purchase method of accounting be used for all business combinations and for an acquirer to be identified for each business combination. SFAS 141(R) modifies existing accounting guidance in the areas of deal and restructuring costs, acquired contingencies, contingent consideration, in- process research and development, accounting for subsequent tax adjustments and assessing the valuation date. This Statement applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. An entity may not apply it before that date. There will be no impact on our financial statements as a result of the adoption of SFAS 141(R), however our accounting for all business combinations after adoption will comply with the new standard.

11

Chemed Corporation and Subsidiary Companies

     In December 2007, the FASB issued Statement No. 160 “Non-controlling Interests in Consolidated Financial Statements — an amendment of ARB No. 51” (“SFAS 160”), which requires ownership interests in subsidiaries held by others to be clearly identified, labeled and presented in the consolidated balance sheet within equity but separate from the parent company’s equity. SFAS 160 also affects the accounting requirements when the parent company either purchases a higher ownership interest or deconsolidates the equity investment. This Statement applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. An entity may not apply it before that date. We currently do not have non-controlling interests in our consolidated financial statements.

     In February 2007, the FASB issued Statement No. 159 “The Fair Value Option for Financial Assets and Financial Liabilities” (“SFAS 159”), which permits an entity to measure certain financial assets and financial liabilities at fair value. Entities that elect the fair value option will report unrealized gains and losses in earnings at each reporting date. The fair value option may be elected on an instrument-by-instrument basis, with a few exceptions, as long as it is applied to the entire instrument. The fair value election is irrevocable unless a new election date occurs. SFAS 159 is effective as of the beginning of the first fiscal year that begins after November 15, 2007. There will be no impact on our financial condition and results of operations as a result of the adoption of SFAS 159.

     In September 2006, the FASB issued Statement No. 157 “Fair Value Measurements”(“SFAS 157”), which addresses how companies should measure fair value when they are required to use a fair value measure for recognition or disclosure purposes under generally accepted accounting principles (GAAP). It sets a common definition of fair value to be used throughout GAAP. The new standard is designed to make the measurement of fair value more consistent and comparable and improve disclosures about those measures. This statement is effective for financial statements issued for fiscal years beginning after November 15, 2007. There will be no impact on our financial condition and results of operations as a result of the adoption of SFAS 157. We are currently evaluating the impact SFAS 157 will have on our footnote disclosures.

2. Long-Term Debt and Lines of Credit

     A summary of our long-term debt follows (in thousands):

	December 31,
	2007			2006
Convertible notes due 2014	$	200,000		$	—
Term loan due 2007-2012		24,500			—
Fixed rate notes due 2011		—			150,000
Other		331			540
Subtotal		224,831			150,540
Less current portion		(10,162	)		(209	)
Long-term debt, less current portion	$	214,669		$	150,331

     The average interest rate for our long-term debt was 4.4% and 8.3% for the years ended December 31, 2007 and 2006, respectively.

2007 REFINANCING

     On May 2, 2007, we entered into a new senior secured credit facility with JPMorgan Chase Bank (the “2007 Facility”) to replace our existing credit facility. The 2007 Facility includes a $100 million term loan, a $175 million revolving credit facility and a $100 million expansion feature. The facility has a 5-year maturity with principal payments on the term loan due quarterly and on the revolving credit facility due at maturity. Interest is payable quarterly at a floating rate equal to our choice of various indices plus a specified margin based on our leverage ratio. The interest rate at the inception of the agreement was LIBOR plus 0.875%. In connection with replacing our existing credit facility, we wrote-off approximately $2.3 million in deferred debt costs. This write-off has been recorded as loss on extinguishment of debt in the accompanying statement of income.

     On May 4, 2007, we used the proceeds from the 2007 Facility to fund the redemption of our $150 million 8.75% Senior Notes due 2011. The redemption was made pursuant to the terms of the indenture at a price of 104.375% plus accrued but unpaid interest. In connection with the redemption, we wrote-off approximately $4.8 million in deferred debt costs. The premium payment of $6.6 million and the write-off of deferred debt costs have been recorded as loss on extinguishment of debt in the accompanying statement of income.

12

Chemed Corporation and Subsidiary Companies

     On May 8, 2007, we entered into a Purchase Agreement with J.P. Morgan Securities Inc. and Citigroup Global Markets Inc. (the “Initial Purchasers”) for issuance and sale of $180 million in aggregate principal amount of our 1.875% Senior Convertible Notes due 2014 (the “Notes”). On May 9, 2007, the Initial Purchasers exercised an over-allotment option to purchase an additional $20 million in aggregate principal amount of Notes. On May 14, 2007, a total of $200 million in aggregate principal amount of the Notes were sold to the Initial Purchasers at a price of $1,000 per Note, less an underwriting fee of $27.50 per Note. The Notes are to be resold by the Initial Purchasers pursuant to Rule 144A of the Securities Act of 1933, as amended (the “Securities Act”).

     We received approximately $194 million in net proceeds from the sale of the Notes after paying underwriting fees, legal and other expenses. Proceeds from the offering were used to purchase treasury shares of our stock, as discussed in Note 22 and to pay down a portion of the 2007 Facility. We pay interest on the Notes on May 15 and November 15 of each year, beginning on November 15, 2007. The Notes mature on May 15, 2014. The Notes are guaranteed on an unsecured senior basis by each of our subsidiaries that are a borrower or a guarantor under any senior credit facility, as defined in the Indenture. The Notes are convertible, under certain circumstances, into our Capital Stock at a conversion rate of 12.3874 shares per $1,000 principal amount of Notes. This conversion rate is equivalent to an initial conversion price of approximately $80.73 per share. Prior to March 1, 2014, holders may convert their Notes under certain circumstances. On and after March 1, 2014, the Notes will be convertible at any time prior to the close of business three days prior to the stated maturity date of the Notes. Upon conversion of a Note, if the conversion value is $1,000 or less, holders will receive cash equal to the lesser of $1,000 or the conversion value of the number of shares of our Capital Stock. If the conversion value exceeds $1,000, in addition to this, holders will receive shares of our Capital Stock for the excess amount. The Indenture contains customary terms and covenants that upon certain events of default, including without limitation, failure to pay when due any principal amount, a fundamental change or certain cross defaults in other agreements or instruments, occurring and continuing; either the trustee or the holders of 25% in aggregate principal amount of the Notes may declare the principal of the Notes and any accrued and unpaid interest through the date of such declaration immediately due and payable. In the case of certain events of bankruptcy or insolvency relating to any significant subsidiary or to us, the principal amount of the Notes and accrued interest automatically becomes due and payable.

     Pursuant to the guidance in EITF 90-19, EITF 00-19 “Accounting for Derivative Instruments Indexed to, and Potentially Settled in a Company’s Own Stock” and EITF 01-6 “The Meaning of Indexed to a Company’s Own Stock,” the Notes are accounted for as convertible debt in the accompanying consolidated balance sheet and the embedded options within the Notes have not been accounted for as separate derivatives.

     We, our subsidiary guarantors and the Initial Purchasers also entered into a Registration Rights Agreement (the “RRA”) dated May 14, 2007. Pursuant to the RRA, we agreed to, no later than the 120th day after May 14, 2007, file a shelf registration statement covering resale of the Notes and the Capital Stock issuable upon conversion pursuant to Rule 415 under the Securities Act. On August 17, 2007, we filed a shelf registration statement, that became immediately effective, to register the Notes and Capital Stock issuable upon conversion.

     On May 8, 2007, we entered into a purchased call transaction and a warrant transaction (written call) with JPMorgan Chase, National Association and Citibank, N.A. (the “Counterparties”). The purchased call options cover approximately 2,477,000 shares of our Capital Stock, which under most circumstances represents the maximum number of shares of Capital Stock that underlie the Notes. Concurrently with entering into the purchased call options, we entered into warrant transactions with each of the Counterparties. Pursuant to the warrant transactions, we sold to the Counterparties warrants to purchase in the aggregate approximately 2,477,000 shares of our Capital Stock. In most cases, the sold warrants may not be exercised prior to the maturity of the Notes.

     The purchased call options and sold warrants are separate contracts with the Counterparties, are not part of the terms of the Notes and do not affect the rights of holders under the Notes. A holder of the Notes will not have any rights with respect to the purchased call options or the sold warrants. The purchased call options are expected to reduce the potential dilution upon conversion of the Notes if the market value per share of the Capital Stock at the time of exercise is greater than approximately $80.73, which corresponds to the initial conversion price of the Notes. The sold warrants have an exercise price of $105.44 and are expected to result in some dilution should the price of our Capital Stock exceed this exercise price.

     Our net cost for these transactions was approximately $27.3 million. Pursuant to EITF 00-19 and EITF 01-6, the purchased call option and the sold warrants are accounted for as equity transactions. Therefore, our net cost was recorded as a decrease in shareholders’ equity in the accompanying consolidated balance sheet.

13

Chemed Corporation and Subsidiary Companies

OTHER

     Other long-term debt has arisen from loans in connection with acquisitions of various businesses and properties. Interest rates range from 5% to 8%, and the obligations are due on various dates through December 2009.

     Since May 2007, we have repaid $75.5 million of the $100 million term note under the 2007 Facility using cash on hand. Of the amount paid, $68.0 million represents a prepayment. The following is a schedule by year of required long-term debt payments as of December 31, 2007 (in thousands):

2008	$	10,162
2009		10,169
2010		4,500
2011		—
2012		—
Thereafter		200,000
Total long-term debt	$	224,831

     During 2007 and 2006, interest totaling $951,000 and $751,000, respectively, was capitalized. Summarized below are the total amounts of interest paid during the years ended December 31 (in thousands):

2007	$	15,466
2006		16,462
2005		19,268

DEBT COVENANTS

     Collectively, the 2007 Facility and the Notes require us to meet certain restrictive financial covenants, in addition to non-financial covenants, including maximum leverage ratios, minimum fixed charge coverage and consolidated net worth ratios, limits on operating leases and minimum asset value limits. We are in compliance with all debt covenants, financial and non-financial, as of December 31, 2007. We have issued $30.1 million in standby letters of credit as of December 31, 2007, mainly for insurance purposes. Issued letters of credit reduce our available credit under the revolving credit agreement. As of December 31, 2007, we have approximately $144.9 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility, excluding the expansion feature.

3. Stock-Based Compensation Plans

     We provide employees the opportunity to acquire our stock through a number of plans, as follows:

• We have six stock incentive plans under which 10,700,000 shares can be issued to key employees through a grant of stock awards and/or options to purchase shares. The Compensation/Incentive Committee (“CIC”) of the Board of Directors administers these plans. All options granted under these plans provide for a purchase price equal to the market value of the stock at the date of grant. The latest plan, covering a total of 3,000,000 shares, was adopted in May 2006 and amended in August 2006. The plans are not qualified, restricted or incentive plans under the U.S. Internal Revenue Code. The terms of each plan differ slightly, however, stock options issued under the plans generally have a maximum term of 10 years. Under one plan, adopted in 1999, up to 500,000 shares may be issued to employees who are not our officers or directors.

• In May 2002, our shareholders approved the adoption of the Executive Long-Term Incentive Plan (“LTIP”) covering our officers and key employees. The CIC periodically approves a pool of shares to be awarded based on stock price hurdles, EBITDA targets and a discretionary component for the LTIP.

14

Chemed Corporation and Subsidiary Companies

The current stock price hurdles were established in 2006, as follows:

Stock Price	Shares to be
Hurdle	Issued
$62.00		20,000
$68.00		30,000
$75.00		30,000
		80,000

	The stock price hurdles must be achieved during 30 trading days out of any 60 trading day period during the three years ending May 15, 2009.
	In February 2007, we met the cumulative EBITDA target established in 2004 and on March 9, 2007 the CIC approved a stock grant of 100,000 shares and the related allocation to participants. The pretax cost of the stock grant was $5.4 million and is included in selling, general and administrative expenses in the accompanying consolidated statement of income.
	In May 2007, the CIC approved a pool of shares to be awarded based on new EBITDA targets. The participants of the LTIP may be awarded 80,000 shares of our capital stock if we attain adjusted EBITDA of either $465 million for the three-year period beginning January 1, 2007, or $604 million for the four-year period beginning January 1, 2007.
	In June 2007, we met the $62.00 per share stock price hurdle and on June 27, 2007, the CIC approved a stock grant of 22,200 shares and the related allocation to participants. The pretax cost of the stock grant was $1.6 million and is included in selling, general and administrative expenses in the accompanying statement of income.
	The pretax cost of the LTIP was $5.5 million for the year ended December 31, 2005. There were no awards made under the LTIP during fiscal 2006. As of December 31, 2007, there are 22,800 shares issuable from the approved discretionary pool.
•	We maintain an Employee Stock Purchase Plan (“ESPP”). The ESPP allows eligible participants to purchase our shares through payroll deductions at current market value. We pay administrative and broker fees associated with the ESPP. Shares purchased for the ESPP are purchased on the open market and credited directly to participants’ accounts. In accordance with the provisions of SFAS 123(R), the ESPP is non-compensatory.

     In March 2005, the Board of Directors approved immediate vesting of all unvested stock options to avoid recognizing approximately $951,000 of pretax expense that would have been charged to income upon adoption of SFAS 123R. The $215,000 pretax charge for accelerating the vesting of these options is included in operating income for the year ended December 31, 2005. For the years ended December 31, 2007 and 2006, we recorded $1.2 million and $1.3 million, respectively, in amortization expense in the accompanying statement of income for stock-based compensation related to the amortization of restricted stock awards granted. For the years ended December 31, 2007 and 2006, we recorded $4.7 million and $1.2 million, respectively, in selling, general and administrative expenses for stock-based compensation related to stock options granted. There were no capitalized stock-based compensation costs as of December 31, 2007.

15

Chemed Corporation and Subsidiary Companies

     The pro-forma disclosure as required by SFAS No. 123 for the year ended December 31, 2005 is as follows (in thousands):

Net income, as reported	$	35,817
Add: stock-based compensation expense included in net income as reported, net of income taxes		4,314
Deduct: total stock-based compensation determined under a fair value method, net of income taxes		(8,519	)
Pro-forma net income	$	31,612
Earnings per share:
As reported	$	1.40
Pro-forma	$	1.24
Diluted earnings per share:
As reported	$	1.36
Pro-forma	$	1.20

     The above pro-forma data were calculated using the Black-Scholes option valuation method to value our stock options granted. Key assumptions include:

Weighted average grant-date fair value of options granted	$	12.43
Risk-free interest rate		4.0	%
Expected volatility		30.9	%
Expected life of options	5 yrs.
Annual dividend rate	$	0.24

     As of December 31, 2007, approximately $3.7 million of total unrecognized compensation costs related to non-vested stock awards are expected to be recognized over a weighted average period of 1.9 years. As of December 31, 2007, approximately $11.7 million of total unrecognized compensation costs related to non-vested stock options are expected to be recognized over a weighted average period of 2.2 years.

     The following table summarizes stock option and award activity:

	Stock Options					Stock Awards
				Weighted					Weighted
	Number			Average		Number			Average
	of			Exercise		of			Grant-Date
	Shares			Price		Shares			Price
Stock-based compensation shares:
Outstanding at January 1, 2007		1,660,522		$	30.53		134,540		$	30.33
Granted		470,600			67.96		174,800			52.35
Exercised/Vested		(236,473	)		24.24		(152,546	)		48.51
Forfeited		(7,100	)		42.41		(1,402	)		29.02
Outstanding at December 31, 2007		1,887,549		$	40.60		155,392		$	37.26
Vested at December 31, 2007		1,173,236		$	27.31

     The weighted average contractual life of outstanding and exercisable options was 5.9 years at December 31, 2007.

16

Chemed Corporation and Subsidiary Companies

     Options outstanding at December 31, 2007, were in the following exercise price ranges:

			Weighted
			Average		Aggregate
	Number of		Exercise		Intrinsic
Exercise Price Range	Options		Price		Value
$16.10 to $35.00		795,282	$	20.15	$	28,415,426
$35.00 to $67.96		1,092,267	$	55.50	$	415,061

     The total intrinsic value of stock options exercised during the years ended December 31, 2007, 2006 and 2005 was $7.8 million, $14.7 million and $28.3 million, respectively. The total intrinsic value of stock options that were vested as of December 31, 2007, 2006 and 2005 was $33.5 million, $16.8 million and $45.4 million, respectively. The total intrinsic value of stock awards vested during the years ended December 31, 2007, 2006 and 2005 was $8.5 million, $1.7 million and $5.6 million, respectively. The total cash received from employees as a result of employee stock option exercises for the years ended December 31, 2007, 2006 and 2005 was $2.5 million, $3.9 million and $12.3 million, respectively. In connection with these exercises, the excess tax benefits realized for the years ended December 31, 2007, 2006 and 2005, were $3.2 million, $5.6 million and $10.8 million, respectively. We settle employee stock options with newly issued shares.

     We estimate the fair value of stock options using the Black-Scholes valuation model, consistent with the provisions of SFAS 123(R), the Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 107 and our prior period pro-forma disclosure of net income including stock-based compensation expense. We determine expected term, volatility, dividend yield and forfeiture rate based on our historical experience. We believe that historical experience is the best indicator of these factors. We granted 470,600 stock options on May 21, 2007, pursuant to the 2006 Stock Incentive Plan. For purposes of determining the key assumptions and the related fair value of the options granted, we analyzed the participants of the LTIP separately from the other stock option recipients. The assumptions we used to value the 2006 and 2007 grants are as follows:

	2007						2006
	LTIP						LTIP
	Participants			All Others			Participants			All Others
Stock price on date of issuance	$	67.96		$	67.96		$	51.76		$	51.76
Grant date fair value per share	$	25.18		$	21.87		$	18.95		$	16.47
Number of options granted		320,000			150,600			262,750			107,700
Expected term (years)		5.8			4.3			6.0			4.5
Risk free rate of return		4.74	%		4.76	%		5.21	%		5.19	%
Volatility		30.4	%		31.3	%		28.0	%		28.9	%
Dividend yield		0.4	%		0.4	%		0.5	%		0.5	%
Forfeiture rate		—	%		5.2	%		—	%		10.0	%

4. Segments and Nature of the Business

     Our segments include the VITAS segment and the Roto-Rooter segment. Relative contributions of each segment to service revenues and sales were 69% and 31%, respectively, in both 2007 and 2006. The vast majority of our service revenues and sales from continuing operations are generated from business within the United States.

     The reportable segments have been defined along service lines, which is consistent with the way the businesses are managed. In determining reportable segments, the Roto-Rooter Services and Roto-Rooter Franchising and Products operating units of the Roto-Rooter segment have been aggregated on the basis of possessing similar operating and economic characteristics. The characteristics of these operating segments and the basis for aggregation are reviewed annually. Accordingly, the reportable segments are defined as follows:

• The VITAS segment provides hospice services for patients with severe, life-limiting illnesses. This type of care is aimed at making the terminally ill patient’s end of life as comfortable and pain-free as possible. Hospice care is typically available to patients who have been initially certified or re-certified as terminally ill (i.e., a prognosis of six months or less) by their attending physician, if any, and the hospice physician. VITAS offers

17

Chemed Corporation and Subsidiary Companies

	all levels of hospice care in a given market, including routine home care, inpatient care and continuous care. Over 90% of VITAS’ revenues are derived through Medicare and Medicaid reimbursement programs.
•	The Roto-Rooter segment provides repair and maintenance services to residential and commercial accounts using the Roto-Rooter registered service mark. Such services include plumbing and sewer, drain and pipe cleaning. They are delivered through company-owned and operated territories, independent contractor-operated territories and franchised locations. This segment also manufactures and sells products and equipment used to provide such services.
•	We report corporate administrative expenses and unallocated investing and financing income and expense not directly related to either segment as “Corporate”. Corporate administrative expense includes the stewardship, accounting and reporting, legal, tax and other costs of operating a publicly held corporation. Corporate investing and financing income and expenses include the costs and income associated with corporate debt and investment arrangements. Historically, we allocated stock-based compensation expense to the segment that employs its recipient. In connection with our adoption of SFAS 123(R) in 2006, we reassessed the classification within our business segments of stock-based compensation expense and determined that our chief decision maker analyzes stock-based compensation as a corporate expense. Accordingly, all stock-based compensation expense for 2007, 2006 and 2005 has been included as a corporate expense in the chart below.

     Segment data for our continuing operations are set forth below (in thousands):

	For the Years Ended December 31,
	2007			2006			2005
Revenues by Type of Service
VITAS
Routine homecare	$	546,872		$	492,012		$	426,380
Continuous care		115,801			121,096			106,417
General inpatient		92,995			89,882			85,836
Medicare cap		(242	)		(3,898	)		—
Total segment		755,426			699,092			618,633
Roto-Rooter
Sewer and drain cleaning		151,111			144,758			134,338
Plumbing repair and maintenance		143,021			129,048			118,783
Independent contractors		22,070			19,169			18,070
HVAC repair and maintenance		3,929			2,821			3,624
Other products and services		24,501			23,699			22,522
Total segment		344,632			319,495			297,337
Total service revenues and sales	$	1,100,058		$	1,018,587		$	915,970
Aftertax Segment Earnings/(Loss)
VITAS	$	59,833		$	48,418		$	33,505
Roto-Rooter		38,851			32,454			27,626
Total		98,684			80,872			61,131
Corporate		(35,909	)		(23,150	)		(24,903	)
Discontinued operations		1,201			(7,071	)		(411	)
Net income	$	63,976		$	50,651		$	35,817
Interest Income
VITAS	$	7,405		$	5,443		$	2,792
Roto-Rooter		5,370			4,082			2,391
Total		12,775			9,525			5,183
Corporate		2,776			2,492			1,805
Intercompany eliminations		(12,247	)		(9,326	)		(4,790	)
Total interest income	$	3,304		$	2,691		$	2,198

18

Chemed Corporation and Subsidiary Companies

	For the Years Ended December 31,
	2007			2006			2005
Interest Expense
VITAS	$	146		$	191		$	153
Roto-Rooter		495			368			563
Total		641			559			716
Corporate		10,603			16,909			20,548
Total interest expense	$	11,244		$	17,468		$	21,264
Income Tax Provision
VITAS	$	35,722		$	28,705		$	20,097
Roto-Rooter		23,856			18,748			16,048
Total		59,578			47,453			36,145
Corporate		(20,515	)		(14,891	)		(17,717	)
Total income tax provision	$	39,063		$	32,562		$	18,428
Identifiable Assets
VITAS	$	529,752		$	517,112		$	523,494
Roto-Rooter		185,982			185,580			179,063
Total		715,734			702,692			702,557
Corporate		56,579			84,890			123,725
Discontinued Operations		—			5,705			12,821
Total identifiable assets	$	772,313		$	793,287		$	839,103
Additions to Long-Lived Assets
VITAS	$	20,435		$	14,419		$	24,462
Roto-Rooter		9,341			10,268			7,938
Total		29,776			24,687			32,400
Corporate		193			137			443
Total additions to long-lived assets	$	29,969		$	24,824		$	32,843
Depreciation and Amortization
VITAS	$	15,430		$	12,669		$	11,504
Roto-Rooter		8,419			7,737			8,361
Total		23,849			20,406			19,865
Corporate		1,539			1,624			1,207
Total depreciation and amortization	$	25,388		$	22,030		$	21,072

5. Goodwill and Intangible Assets

     Amortization of definite-lived intangible assets from continuing operations was $4.0 million for each of the years ended December 31, 2007, 2006 and 2005, respectively. The following is a schedule by year of projected amortization expense for definite-lived intangible assets (in thousands):

2008	$	4,032
2009		4,002
2010		1,996
2011		1,197
2012		1,197
Thereafter		1,453

19

Chemed Corporation and Subsidiary Companies

     The balance in identifiable intangible assets comprises the following (in thousands):

	Gross		Accumulated			Net Book
	Asset		Amortization			Value
December 31, 2007
Referral networks	$	21,140	$	(10,650	)	$	10,490
Covenants not to compete		8,753		(5,624	)		3,129
Customer lists		1,229		(971	)		258
Subtotal — definite-lived intangibles		31,122		(17,245	)		13,877
VITAS trade name		51,300		—			51,300
Total	$	82,422	$	(17,245	)	$	65,177
December 31, 2006
Referral networks	$	21,142	$	(7,858	)	$	13,284
Covenants not to compete		8,751		(4,433	)		4,318
Customer lists		1,223		(910	)		313
Subtotal — definite-lived intangibles		31,116		(13,201	)		17,915
VITAS trade name		51,300		—			51,300
Total	$	82,416	$	(13,201	)	$	69,215

     The $6.1 million increase in goodwill during 2006 and 2007 relates to business combinations within the Roto-Rooter segment and adjustments to purchase price allocations.

     As discussed in Note 23, in 2006 we changed the date of our annual goodwill and indefinite-lived intangible asset impairment analysis to October 1. For all reporting units included in continuing operations, the impairment tests indicated that our goodwill and VITAS trade name are not impaired. For the purpose of impairment testing, we consider the reporting units to be VITAS, Roto-Rooter Services (plumbing and drain cleaning services) and Roto-Rooter Franchising and Products (franchising and manufacturing and sale of plumbing and drain cleaning products). As further discussed in Note 7, VITAS sold its Phoenix program in November 2006. Prior to that sale, we determined that the acquired referral network was impaired and recorded a pretax impairment loss of $2.2 million during September 2006.

6. Other Expenses

     Other expenses from continuing operations include the following pretax charges (in thousands):

	For the Year Ended
	December 31,
	2007			2006		2005
Costs related to class action litigation	$	1,927		$	272	$	17,350
Adjustments to transaction-related costs of the VITAS acquisition		—			—		(959	)
Gain on sale of property		(1,138	)		—		—
Total other expenses	$	789		$	272	$	16,391

20

Chemed Corporation and Subsidiary Companies

7. Discontinued Operations

     Discontinued operations comprise (in thousands, except per share amounts):

	For the Years Ended December 31,
	2007			2006			2005
Phoenix (2006):
Income/(loss) before income taxes	$	1,938		$	(9,117	)	$	2,627
Income taxes		(737	)		3,645			(1,150	)
Income/(loss) from operations, net of income taxes		1,201			(5,472	)		1,477
Gain on disposal, net of income tax expense of $391		—			600			—
		1,201			(4,872	)		1,477
Service America (2004):
Income/(loss) before income taxes		—			(141	)		576
Income taxes		—			109			(241	)
Income/(loss) from operations, net of income taxes		—			(32	)		335
(Loss)/gain on disposal, net of income tax benefit of $165 and $14,232 respectively		—			—			(2,148	)
		—			(32	)		(1,813	)
Adjustment to accruals of operations discontinued in prior years:
Settlement costs and other accruals (2002)		—			(2,246	)		(120	)
Environmental accruals (1991)		—			(1,194	)		—
Allowance for uncollectible notes receivable and other accruals (2001)		—			28			—
Loss before income taxes		—			(3,412	)		(120	)
All other income taxes		—			1,245			45
Total adjustments		—			(2,167	)		(75	)
Total discontinued operations	$	1,201		$	(7,071	)	$	(411	)
Earnings/(loss) per share	$	0.05		$	(0.27	)	$	(0.02	)
Diluted earnings/(loss) per share	$	0.05		$	(0.26	)	$	(0.02	)

     In September 2006, our Board of Directors approved and we announced our intention to exit the hospice market in Phoenix, Arizona. Although we were successful in growing admissions of terminally ill patients, our growth was primarily patients who reside in assisted living settings. Patients residing in these types of facilities tend to exit curative care and enter into hospice care relatively early in their terminal diagnosis. The Medicare Cap limits payment for hospice care when a significant portion of the patient census enters into hospice early in their terminal diagnosis. Although we have, on average, relatively short average and median lengths of stay in the majority of our programs, all programs are measured separately and cannot be considered in the aggregate of programs under common control. Due to these billing limitations, we experienced significant operating losses at this program. As a result of our announcement, we performed impairment tests of our long-lived assets of the Phoenix operation as of September 30, 2006, in accordance with Statement of Financial Accounting Standards No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets.” An impairment charge of $2.4 million was recorded for the referral network intangible asset and fixed assets during the third quarter of 2006. The sale was completed in November 2006. The acquiring corporation purchased the substantial majority of assets of the Phoenix program for $2.5 million. In October 2007, we received notification from the Federal government’s fiscal intermediary regarding our Medicare cap liabilities related to the 2006 measurement period. The notification revealed that we were over accrued at our discontinued Phoenix operation by $1.9 million. We have recorded the reversal of this over accrual and its related tax effects in discontinued operations during the year ended December 31, 2007. As of December 31, 2007, we have $500,000 accrued for potential retroactive billings related to the Medicare Cap for Phoenix.

     On September 28, 2006, we announced a preliminary settlement in regard to litigation related to the 2002 divestiture of our Patient Care business segment. Prior to the settlement, we had a long-term receivable from Patient Care of $12.5 million. We also had current accounts receivable from Patient Care for the post-closing balance sheet valuation and for expenses paid by us after closing on Patient Care’s behalf of $3.4 million. We were in litigation with Patient Care over the collection of these current amounts and their allegations that our acquisition of VITAS violated a non-compete

21

Chemed Corporation and Subsidiary Companies

covenant in the sales agreement. We agreed to forgive $1.2 million of the current receivable related to the post-closing balance sheet valuation and convert the remaining amount into debt secured by a promissory note with the same terms as the $12.5 million long-term receivable. We incurred additional costs related to the settlement of $1.1 million for additional insurance and legal costs related to workers’ compensation claims incurred prior to the sale. The aftertax charge related to these amounts of $1.5 million has been recorded as discontinued operations in 2006.

     In December 2007, the parties amended the terms of the long-term notes receivable from Patient Care. We agreed to waive the prepayment penalty provisions in the notes provided that Patient Care paid $5 million of principal on or before December 31, 2007, and the remaining outstanding principal on or before March 31, 2008. On December 31, 2007, we received a principal payment of $5 million from Patient Care. Subsequent to year-end, we received principal payments of $5.7 million from Patient Care.

     We also have a warrant to purchase 2% of Patient Care’s common stock that we recorded as a $1.4 million investment. As a result of financial information received in 2006, we determined that the value of the warrants was permanently impaired and recorded a pretax impairment charge of $1.4 million. This charge is included in income from continuing operations on the consolidated statement of income for the year ended December 31, 2006.

     In December 2004, the Board of Directors authorized the discontinuance of our Service America segment through an asset sale to employees of Service America. The disposal was completed in May 2005. Our decision to dispose of Service America, which provides major-appliance and heating/air conditioning repair, maintenance and replacement services, was based on declining operating results and projected operating losses. The acquiring corporation purchased the substantial majority of Service America’s assets in exchange for assuming substantially all of Service America’s liabilities. The loss on disposal of Service America in 2005 arises from the finalization of asset and liability values and related tax benefits resulting from the consummation of the sale transaction.

     During 2006, we increased our accrual for environmental liabilities related to the disposal of DuBois Chemical, Inc., by $1.2 million. The adjustment made by us is based on an assessment by our environmental attorney, a preliminary settlement agreement with respect to one site and ongoing discussions with the U.S. Environmental Protection Agency. At December 31, 2007 and 2006, the accrual for our estimated liability for potential environmental cleanup and related costs arising from the sale of DuBois amounted to $1.7 million and $3.5 million, respectively. Of the 2007 balance, $826,000 is included in other current liabilities and $900,000 is included in other liabilities (long-term). We are contingently liable for additional DuBois-related environmental cleanup and related costs up to a maximum of $14.9 million. On the basis of a continuing evaluation of the potential liability, we believe it is not probable this additional liability will be paid. Accordingly, no provision for this contingent liability has been recorded. The potential liability is not insured, and the recorded liability does not assume the recovery of insurance proceeds. Also, the environmental liability has not been discounted because it is not possible to reliably project the timing of payments. We believe that any adjustments to our recorded liability will not materially adversely affect our financial position or results of operations.

     Revenues generated by discontinued operations comprise (in thousands):

	For the Years Ended December 31,
	2007		2006			2005
Service America	$	—	$	—		$	10,716
Phoenix		1,938		(98	)		10,506
	$	1,938	$	(98	)	$	21,222

     At December 31, 2007, other current liabilities include accruals of $1.3 million and other liabilities (long-term) include accruals of $1.2 million for costs related to discontinued operations. The estimated timing of payments of these liabilities follows (in thousands):

2008	$	1,345
2009		963
2010		208
Thereafter		—
	$	2,516

22

Chemed Corporation and Subsidiary Companies

8. Business Combinations

     During 2007, we completed one business combination within the Roto-Rooter segment for $1.1 million in cash to increase our market penetration in Burlington, Vermont. We made no acquisitions within the VITAS segment during 2007.

     During 2006, we completed three business combinations within the Roto-Rooter segment for an aggregate purchase price of $4.1 million in cash. We made no acquisitions within the VITAS segment during 2006. The Roto-Rooter acquisitions were completed mainly to increase our market penetration in Erie, Pennsylvania; Tyler, Texas; and Lexington, Kentucky.

     During 2005, we completed one business combination within the Roto-Rooter segment and two within the VITAS segment for an aggregate purchase price of $6.2 million in cash. The acquisitions were completed mainly to increase our market penetration. The VITAS businesses acquired provide hospice services in the Pittsburgh, Pennsylvania and Philadelphia, Pennsylvania areas and the Roto-Rooter business acquired provides drain cleaning and plumbing services using the Roto-Rooter name in Greensboro, North Carolina.

          The unaudited pro-forma results of operations, assuming purchase business combinations completed in 2007 and 2006 were completed on January 1, 2006, do not materially impact the accompanying consolidated financial statements. The results of operations of each of the above business combinations are included in our results of operations from the date of the respective acquisition. The allocations of purchase price are immaterial to the accompanying consolidated financial statements.

9. Other Income—Net

     Other income—net from continuing operations comprises the following (in thousands):

	For the Years Ended December 31,
	2007			2006			2005
Interest income	$	3,304		$	2,691		$	2,198
Gain on trading investments of employee benefit trust		963			2,030			863
Loss on disposal of property and equipment		(286	)		(161	)		(131	)
Other — net		144			88			192
Total other income	$	4,125		$	4,648		$	3,122

10. Income Taxes

     The provision for income taxes comprises the following (in thousands):

	For the Years Ended December 31,
	2007		2006			2005
Continuing Operations:
Current
U.S. federal	$	26,458	$	21,955		$	21,201
U.S. state and local		3,995		2,808			1,763
Foreign		497		391			519
Deferred
U.S. federal, state and local		8,057		7,474			(4,951	)
Foreign		56		(66	)		(104	)
Total	$	39,063	$	32,562		$	18,428
Discontinued Operations:
Current U.S. federal	$	647	$	(4,175	)	$	(14,497	)
Current U.S. state and local		90		(440	)		(1,214	)
Deferred U.S. federal, state and local		—		7			16,892
Total	$	737	$	(4,608	)	$	1,181

23

Chemed Corporation and Subsidiary Companies

     A summary of the temporary differences that give rise to deferred tax assets/(liabilities) follows (in thousands):

	December 31,
	2007			2006
Accrued liabilities	$	26,557		$	27,248
Amortization of original issue discount		18,602			—
Stock compensation expense		2,126			442
Allowance for uncollectible accounts receivable		1,226			2,692
State net operating loss carryforwards		1,514			1,427
Other		2,789			3,114
Deferred income tax assets		52,814			34,923
Amortization of intangible assets		(33,928	)		(32,162	)
Accelerated tax depreciation		(8,268	)		(8,222	)
Currents assets		(1,651	)		(1,776	)
Other		(310	)		(701	)
Deferred income tax liabilities		(44,157	)		(42,861	)
Net deferred income tax assets	$	8,657		$	(7,938	)

     Included in other assets at December 31, 2007, are deferred income tax assets of $247,000 ( 2006 — $574,000). At December 31, 2007 and 2006, state net operating loss carryforwards were $ 37.4 million and $29.0 million, respectively. These net operating losses will expire, in varying amounts, between 2009 and 2026. Based on our history of operating earnings, we have determined that our operating income will, more likely than not, be sufficient to ensure realization of our deferred income tax assets. We believe no net operating losses will be lost due to the continuity of business requirement.

     The cumulative effect upon adoption of FIN 48 was to reduce our accrual for uncertain tax positions by approximately $4.7 million, which has been recorded in retained earnings as of January 1, 2007 in the accompanying consolidated balance sheet. After adoption, we had approximately $1.3 million in unrecognized tax benefits. The majority of this amount would affect our effective tax rate, if recognized in a future period. The years ended December 31, 2004 and forward remain open for review for Federal income tax purposes. The earliest open year relating to any of our material state jurisdictions is the fiscal year ended December 31, 2002. During the next twelve months, we do not anticipate a material net change in unrecognized tax benefits.

     As permitted by FIN 48, we reclassified interest related to our accrual for uncertain tax positions to separate interest accounts. We believe this change in accounting method is preferable as it more accurately classifies the impact of interest in our consolidated financial statements. As of December 31, 2007, we have approximately $142,000 accrued in interest payable related to uncertain tax positions. These accruals are included in other current liabilities in the accompanying consolidated balance sheet. Net interest expense related to uncertain tax positions included in interest expense in the accompanying consolidated statement of income is not material.

     A roll forward of the significant changes to our unrecognized tax benefits is as follows (in thousands):

Balance after adoption January 1, 2007	$	1,281
Unrecognized tax benefits due to positions taken in 2007		178
Decrease due to settlement with taxing authorities		(40	)
Decrease due to expiration of statute of limitations		(250	)
Ending balance December 31, 2007	$	1,169

24

Chemed Corporation and Subsidiary Companies

     The difference between the actual income tax provision for continuing operations and the income tax provision calculated at the statutory U.S. federal tax rate is explained as follows (in thousands):

	For the Years Ended December 31,
	2007			2006			2005
Income tax provision calculated using the statutory rate of 35%	$	35,643		$	31,599		$	19,130
State and local income taxes, less federal income tax effect		3,998			3,112			1,994
Tax accrual adjustments		(765	)		(1,758	)		(2,387	)
Other —net		187			(391	)		(309	)
Income tax provision	$	39,063		$	32,562		$	18,428
Effective tax rate		38.4	%		36.1	%		33.7	%

     Summarized below are the total amounts of income taxes paid/(refunded) during the years ended December 31 (in thousands):

2007	$	24,345
2006		3,823
2005		9,923

     Provision has not been made for additional taxes on $35.1 million of undistributed earnings of our domestic subsidiaries. Should we elect to sell our interest in all of these businesses rather than to effect a tax-free liquidation, additional taxes amounting to approximately $12.8 million would be incurred based on current income tax rates.

11. Cash Overdrafts and Cash Equivalents

     Included in accounts payable are cash overdrafts of $9.5 million and $10.6 million as of December 31, 2007 and 2006, respectively.

     From time to time throughout the year, we invest excess cash in repurchase agreements directly with major commercial banks. We do not physically hold the collateral, but the term of such repurchase agreements is less than 10 days. Investments of significant amounts are spread among a number of banks and the amounts invested in each bank are varied constantly. Included in cash and cash equivalents at December 31, 2007, are cash equivalents in the amount of $3.4 million (2006 — $22.5 million). The cash equivalents at both dates consist of investments in various money market funds and repurchase agreements yielding interest at a weighted average rate of 2.8% in 2007 and 5.2% in 2006.

12. Properties and Equipment

     A summary of properties and equipment follows (in thousands):

	December 31,
	2007			2006
Land	$	1,355		$	1,713
Buildings		27,159			24,349
Transportation equipment		12,237			12,270
Machinery and equipment		46,927			42,474
Computer software		22,839			21,223
Furniture and fixtures		38,770			31,017
Projects under development		13,865			14,201
Total properties and equipment		163,152			147,247
Less accumulated depreciation		(88,639	)		(77,107	)
Net properties and equipment	$	74,513		$	70,140

     The net book value of computer software at December 31, 2007 and 2006, was $7.6 million and $8.1 million, respectively. Depreciation expense for computer software was $4.4 million, $4.0 million and $4.3 million for the years ended December 31, 2007, 2006 and 2005, respectively.

25

Chemed Corporation and Subsidiary Companies

13. Other Current Liabilities

     Other current liabilities comprised the following (in thousands):

	December 31,
	2007		2006
Accrued legal settlements	$	2,393	$	1,889
Accrued divestiture expenses		845		2,612
Accrued Medicare Cap estimate		500		3,373
Other		10,191		14,810
Total other current liabilities	$	13,929	$	22,684

14. Pension and Retirement Plans

     Retirement obligations under various plans cover substantially all full-time employees who meet age and/or service eligibility requirements. The major plans providing retirement benefits to our employees are defined contribution plans. Expenses charged to continuing operations for our retirement and profit-sharing plans, ESOPs, excess benefit plans and other similar plans comprise the following (in thousands):

	For the Years Ended December 31,
	2007		2006		2005
Compensation cost of ESOPs	$	—	$	—	$	1,324
Pension, profit-sharing and other similar plans		12,797		11,117		9,004
Total	$	12,797	$	11,117	$	10,328
Dividends on ESOP shares
used for debt service	$	—	$	—	$	122

     We have excess benefit plans for key employees whose participation in the qualified plans is limited by U.S. Employee Retirement Income Security Act requirements. Benefits are determined based on theoretical participation in the qualified plans. Benefits are only invested in mutual funds, and participants are not permitted to diversify accumulated benefits in shares of our stock. Trust assets invested in shares of our stock are included in treasury stock, and the corresponding liability is included in a separate component of shareholders’ equity. At December 31, 2007, these trusts held 134,104 shares or $2.5 million of our stock (2006 – 133,315 shares or $2.4 million). The diversified assets of our excess benefit and deferred compensation plans, all of which are invested in either company-owned life insurance or various mutual funds, totaled $29.4 million at December 31, 2007 (2006 — $25.7 million).

15. Lease Arrangements

     We have operating leases that cover our corporate office headquarters, various warehouse and office facilities, office equipment and transportation equipment. The remaining terms of these leases range from one year to nine years, and in most cases we expect that these leases will be renewed or replaced by other leases in the normal course of business. We have no significant capital leases as of December 31, 2007 or 2006.

     The following is a summary of future minimum rental payments and sublease rentals to be received under operating leases that have initial or remaining noncancelable terms in excess of one year at December 31, 2007 (in thousands):

2008	$	15,010
2009		12,984
2010		9,105
2011		6,846
2012		4,265
After 2012		6,425
Total minimum rental payments		54,635
Less: minimum sublease rentals		(397	)
Net minimum rental payments	$	54,238

26

Chemed Corporation and Subsidiary Companies

     Total rental expense incurred under operating leases for continuing operations follows (in thousands):

	For the Years Ended December 31,
	2007			2006			2005
Total rental payments	$	17,307		$	16,859		$	17,027
Less sublease rentals		(260	)		(687	)		(1,659	)
Net rental expense	$	17,047		$	16,172		$	15,368

16. Financial Instruments

     The following methods and assumptions are used in estimating the fair value of each class of our financial instruments:

• For cash and cash equivalents, accounts receivable and accounts payable, the carrying amount is a reasonable estimate of fair value because of the liquidity and short-term nature of these instruments.

• The December 31, 2007 and 2006, carrying value of $9.7 million and $14.7 million, respectively related to our investment in the note receivable due from Patient Care is considered to be the best available indicator of fair value.

• For long-term debt, we calculated the fair value based either on market quotations or discounted cash flow analysis. The estimated fair value of our long-term debt is $210.5 million and $155.0 million as of December 31, 2007 and 2006, respectively.

17. Earnings Per Share

     The computation of earnings per share follows (in thousands, except per share data):

	Income from Continuing Operations						Net Income
For the Years Ended					Earnings						Earnings
December 31,	Income		Shares		per Share		Income		Shares		per Share
2007
Earnings	$	62,775		24,520	$	2.56	$	63,976		24,520	$	2.61
Dilutive stock options		—		456				—		456
Nonvested stock awards		—		101				—		101
Diluted earnings	$	62,775		25,077	$	2.50	$	63,976		25,077	$	2.55
2006
Earnings	$	57,722		26,118	$	2.21	$	50,651		26,118	$	1.94
Dilutive stock options		—		496				—		496
Nonvested stock awards		—		55				—		55
Diluted earnings	$	57,722		26,669	$	2.16	$	50,651		26,669	$	1.90
2005
Earnings	$	36,228		25,552	$	1.42	$	35,817		25,552	$	1.40
Dilutive stock options		—		666				—		666
Nonvested stock awards		—		81				—		81
Diluted earnings	$	36,228		26,299	$	1.38	$	35,817		26,299	$	1.36

     During 2007, 290,096 stock options were excluded from the computation of diluted earnings per share as their exercise prices were greater than the average market price during most of the year. During 2006, 369,850 stock options were excluded from the computation of diluted earnings per share as their exercise prices were greater than the average market price during most of the year. During 2005, there were no options outstanding whose exercise price exceeded the average market price for the year.

27

Chemed Corporation and Subsidiary Companies

18. Loans Receivable from Independent Contractors

     At December 31, 2007, we had contractual arrangements with 61 independent contractors to provide plumbing repair and drain cleaning services under sublicensing agreements using the Roto-Rooter name in lesser-populated areas of the United States and Canada. The arrangements give the independent contractors the right to conduct a plumbing and drain cleaning business using the Roto-Rooter name in a specified territory in exchange for a royalty based on a percentage of labor sales, generally approximately 40%. We also pay for yellow pages advertising in these areas, provide certain capital equipment and provide operating manuals to serve as resources for operating a plumbing and drain cleaning business. The contracts are generally cancelable upon 90 days’ written notice (without cause) or upon a few days’ notice (with cause). The independent contractors are responsible for running the businesses as they believe best.

     Our maximum exposure to loss from arrangements with our independent contractors at December 31, 2007, is approximately $1.6 million (2006 — $1.9 million). The exposure to loss is mainly the result of loans provided to the independent contractors. In most cases, these loans are partially secured by receivables and equipment owned by the independent contractor. The interest rates on the loans range from zero to 8% per annum, and the remaining terms of the loans range from 2.5 months to 5.4 years at December 31, 2007. During 2007, we recorded revenues of $22.1 million (2006 — $19.2 million; 2005 — $18.1 million) and pretax profits of $9.0 million (2006 — $6.9 million; 2005 — $6.0 million) from all of our independent contractors.

19. Litigation

     Like other large California employers, our VITAS subsidiary faces allegations of purported class-wide wage and hour violations. It was party to a class action lawsuit filed in the Superior Court of California, Los Angeles County, in April of 2004 by Ann Marie Costa, Ana Jimenez, Mariea Ruteaya and Gracetta Wilson (“Costa”). This case alleged failure to pay overtime wages for hours worked “off the clock” on administrative tasks, including voicemail retrieval, time entry, travel to and from work, and pager response. This case also alleged VITAS failed to provide meal and break periods to a purported class of California nurses, home health aides and licensed clinical social workers. The case also sought payment of penalties, interest, and Plaintiffs’ attorney fees. VITAS contested these allegations. During 2006, we reached a tentative settlement and on June 26, 2006, the court granted final approval of the settlement ($19.9 million).

     VITAS is party to a class action lawsuit filed in the Superior Court of California, Los Angeles County, in September 2006 by Bernadette Santos, Keith Knoche and Joyce White (“Santos”). This case, filed by the Costa case Plaintiffs’ counsel, makes similar allegations of failure to pay overtime and failure to provide meal and rest periods to a purported class of California admissions nurses, chaplains and sales representatives. The case likewise seeks payment of penalties, interest and Plaintiffs’ attorney fees. VITAS contests these allegations. The lawsuit is in its early stage and we are unable to estimate our potential liability, if any, with respect to these allegations.

     In April 2007, our Roto-Rooter subsidiary was named in a class action lawsuit filed in San Mateo Superior Court by Stanley Ita (“Ita”) alleging class-wide wage and hour violations at one California branch. This suit alleges failure to provide meal and break periods, credit for work time beginning from the first call to dispatch rather than arrival at first assignment and improper calculations of work time and overtime. The case sought payment of penalties, interest and Plaintiffs’ attorney fees. After the suit was filed, we offered a settlement to the members of the class and paid approximately $200,000. In January 2008, we agreed to a tentative settlement with the remaining members of the class for approximately $1.8 million. The tentative settlement is subject to court approval. The tentative settlement has been accrued in the accompanying financial statements as of and for the year ended December 31, 2007.

     Regardless of outcome, defense of litigation adversely affects us through defense costs, diversion of our time and related publicity. In the normal course of business, we are a party to various claims and legal proceedings. We record a reserve for these matters when an adverse outcome is probable and the amount of the potential liability is reasonably estimable.

28

Chemed Corporation and Subsidiary Companies

20. OIG Investigation

     In April 2005, the Office of Inspector General (“OIG”) for the Department of Health and Human Services served VITAS with civil subpoenas relating to VITAS’ alleged failure to appropriately bill Medicare and Medicaid for hospice services. As part of this investigation, the OIG selected medical records for 320 past and current patients from VITAS’ three largest programs for review. It also sought policies and procedures dating back to 1998 covering admissions, certifications, recertifications and discharges. During the third quarter of 2005 and again in May 2006, the OIG requested additional information from us. The Court dismissed a related qui tam complaint filed in U.S. District Court for the Southern District of Florida with prejudice in July 2007. The plaintiffs are appealing this dismissal. Pretax expenses related to complying with OIG requests have been immaterial in 2007. We incurred pretax expense related to complying with OIG requests and defending the litigation of $1.1 million and $637,000 for the years ended December 31, 2006 and 2005, respectively.

     The government continues to investigate the complaint’s allegations. We are unable to predict the outcome of this matter or the impact, if any, that the investigation may have on our business, results of operations, liquidity or capital resources. Regardless of outcome, responding to the subpoenas and defending the litigation can adversely affect us through defense costs, diversion of our time and related publicity.

21. Related Party Transactions

     In October 2004, VITAS entered into a pharmacy services agreement (“Agreement”) with Omnicare, Inc. (“OCR”) whereby OCR provides specified pharmacy services for VITAS and its hospice patients in geographical areas served by both VITAS and OCR. The Agreement has an initial term of three years that renews automatically for one-year terms. Either party may cancel the Agreement at the end of any term by giving written notice at least 90 days prior to the end of said term. In June 2004, VITAS entered into a pharmacy services agreement with excelleRx. The agreement has a one-year term and automatically renews unless either party provides a 90-day written termination notice. Subsequent to June 2004, OCR acquired excelleRx. Under both agreements, VITAS made purchases of $33.6 million, $30.4 million and $16.2 million for the years ended December 31, 2007, 2006 and 2005, respectively, and has accounts payable of $445,000 and $4.0 million at December 31, 2007 and 2006, respectively.

     Mr. E. L. Hutton is non-executive Chairman of the Board and a director of the Company and OCR. Mr. Joel F. Gemunder, President and Chief Executive Officer of OCR, Mr. Charles H. Erhart, Jr. and Ms. Sandra Laney are directors of both OCR and the Company. Mr. Kevin J. McNamara, President, Chief Executive Officer and a director of the Company, is a director emeritus of OCR. We believe that the terms of these agreements are no less favorable to VITAS than we could negotiate with an unrelated party.

22. Capital Stock Transactions

     On April 26, 2007, our Board of Directors authorized a $150 million stock repurchase program. For the year ended December 31, 2007, we repurchased 2,139,401 shares at a weighted average cost per share of $59.77 under the April 2007 and July 2006 programs. For the year ended December 31, 2006, we repurchased 433,580 shares at a weighted average cost per share of $36.01 under the July 2006 and February 2000 programs.

     On May 15, 2006, our shareholders approved an amendment to our Certificate of Incorporation increasing the number of authorized shares of capital stock from 40 million shares to 80 million shares.

     On March 11, 2005, our Board of Directors approved a 2-for-1 stock split in the form of a 100% stock dividend to shareholders of record at the close of business on April 22, 2005. This stock split was paid May 11, 2005. Under Delaware law, the par value of the capital stock remains $1 per share.

23. Change in Accounting Principle

     Effective September 30, 2006, we changed the date of our annual goodwill impairment analysis to October 1. Previously, we performed this annual goodwill impairment test on December 31. We believe this change in accounting principle is preferable because the new date coincides with the Federal government’s fiscal year end of September 30 and therefore allows for a better estimation of the Medicare related cash flows of our VITAS business. Medicare pays in excess of 90% of VITAS’ revenue. Of the total goodwill recorded as of September 30, 2006, approximately 75% is related to VITAS. Due to the Medicare Cap discussed above, October 1 is when cash flows from our hospice programs are most predictable. The change in accounting principle had no effect on our consolidated financial statements.

29

Chemed Corporation and Subsidiary Companies

24. Guarantor Subsidiaries

     Our 1.875% Senior Convertible Notes issued on May 14, 2007, are fully and unconditionally guaranteed on an unsecured, joint and severally liable basis by certain of our 100% owned subsidiaries. The equity method has been used with respect to the parent company’s (Chemed) investment in subsidiaries. No consolidating adjustment column is presented for the condensed consolidating statement of cash flow since there were no significant consolidating entries for the periods presented. The following condensed, consolidating financial data presents the composition of the parent company, the guarantor subsidiaries and the non-guarantor subsidiaries as of December 31, 2007 and 2006, and for the periods ended December 31, 2007, 2006 and 2005 (in thousands):

Condensed Consolidating Balance Sheet

December 31, 2007

				Guarantor			Non-Guarantor			Consolidating
	Parent			Subsidiaries			Subsidiaries			Adjustments			Consolidated
ASSETS
Cash and cash equivalents	$	3,877		$	(1,584	)	$	2,695		$	—		$	4,988
Accounts receivable, less allowances		706			101,843			564			—			103,113
Intercompany receivables		42,241			—			(3,925	)		(38,316	)		—
Inventories		—			6,116			480			—			6,596
Current deferred income taxes		130			13,964			118			—			14,212
Prepaid expenses and other current assets		884			9,521			91			—			10,496
Total current assets		47,838			129,860			23			(38,316	)		139,405
Investments of deferred compensation plans held in trust		—			—			29,417			—			29,417
Notes receivable		9,701			—			—			—			9,701
Properties and equipment, at cost, less accumulated depreciation		4,306			68,303			1,904			—			74,513
Identifiable intangible assets less accumulated amortization		—			65,176			1			—			65,177
Goodwill		—			433,946			4,743			—			438,689
Other assets		12,658			2,450			303			—			15,411
Investments in subsidiaries — Guarantor Subs		500,288			—			—			(500,288	)		—
Investments in subsidiaries — Non-Guarantor Subs		664			11,005			—			(11,669	)		—
Total assets	$	575,455		$	710,740		$	36,391		$	(550,273	)	$	772,313
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	$	(1,236	)	$	48,978		$	369		$	—		$	48,111
Intercompany payables		—			34,992			3,324			(38,316	)		—
Current portion of long-term debt		10,000			162			—			—			10,162
Income taxes		1,137			3,034			50			—			4,221
Accrued insurance		255			36,082			—			—			36,337
Accrued compensation		3,882			35,505			685			—			40,072
Other current liabilities		2,047			10,486			1,396			—			13,929
Total current liabilities		16,085			169,239			5,824			(38,316	)		152,832
Deferred income taxes		(23,174	)		39,247			(10,271	)		—			5,802
Long-term debt		214,500			169			—			—			214,669
Deferred compensation liabilities		—			—			29,149			—			29,149
Other liabilities		3,695			1,797			20			—			5,512
Stockholders’ equity		364,349			500,288			11,669			(511,957	)		364,349
Total liabilities and stockholders’ equity	$	575,455		$	710,740		$	36,391		$	(550,273	)	$	772,313

30

Chemed Corporation and Subsidiary Companies

December 31, 2006

				Guarantor			Non-Guarantor		Consolidating
	Parent			Subsidiaries			Subsidiaries		Adjustments			Consolidated
ASSETS
Cash and cash equivalents	$	25,258		$	(1,314	)	$	5,330	$	—		$	29,274
Accounts receivable, less allowances		1,547			91,065			474		—			93,086
Intercompany receivables		84,784			—			—		(84,784	)		—
Inventories		—			6,169			409		—			6,578
Current deferred income taxes		(117	)		17,591			315		—			17,789
Current assets of discontinued operations		—			5,418			—		—			5,418
Prepaid expenses and other current assets		809			9,087			72		—			9,968
Total current assets		112,281			128,016			6,600		(84,784	)		162,113
Investments of deferred compensation plans held in trust		12,214			13,499			—		—			25,713
Notes receivable		14,701			—			—		—			14,701
Properties and equipment, at cost, less accumulated depreciation		6,412			62,023			1,705		—			70,140
Identifiable intangible assets less accumulated amortization		—			69,213			2		—			69,215
Goodwill		—			430,671			4,379		—			435,050
Non-current assets of discontinued operations		—			287			—		—			287
Other assets		12,845			2,514			709		—			16,068
Investments in subsidiaries		430,399			8,628			—		(439,027	)		—
Total assets	$	588,852		$	714,851		$	13,395	$	(523,811	)	$	793,287
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	$	(189	)	$	49,502		$	431	$	—		$	49,744
Intercompany payables		—			84,036			748		(84,784	)		—
Current portion of long-term debt		—			209			—		—			209
Income taxes		(5,906	)		11,680			991		—			6,765
Accrued insurance		2,938			35,519			—		—			38,457
Accrued compensation		2,530			32,731			729		—			35,990
Current liabilities of discontinued operations		—			12,215			—		—			12,215
Other current liabilities		9,568			11,715			1,401		—			22,684
Total current liabilities		8,941			237,607			4,300		(84,784	)		166,064
Deferred income taxes		(6,946	)		32,780			467		—			26,301
Long-term debt		150,000			331			—		—			150,331
Deferred compensation liabilities		12,247			13,267			—		—			25,514
Other liabilities		3,249			467			—		—			3,716
Stockholders’ equity		421,361			430,399			8,628		(439,027	)		421,361
Total liabilities and stockholders’ equity	$	588,852		$	714,851		$	13,395	$	(523,811	)	$	793,287

31

Chemed Corporation and Subsidiary Companies

Condensed Consolidating Income Statement

				Guarantor			Non-Guarantor			Consolidating
For the year ended December 31, 2007	Parent			Subsidiaries			Subsidiaries			Adjustments			Consolidated
Continuing Operations
Net sales and service revenues	$	—		$	1,075,042		$	25,016		$	—		$	1,100,058
Cost of services provided and goods sold		—			754,739			12,327			—			767,066
Selling, general and administrative expenses		18,846			159,074			6,140			—			184,060
Depreciation		488			19,003			627			—			20,118
Amortization		1,232			4,036			2			—			5,270
Other operating expenses — net		(1,138	)		1,927			—			—			789
Total costs and expenses		19,428			938,779			19,096			—			977,303
Income/(loss) from operations		(19,428	)		136,263			5,920			—			122,755
Interest expense		(10,610	)		(445	)		(189	)		—			(11,244	)
Loss on extinguishment of debt		(13,798	)		—			—			—			(13,798	)
Other income — net		15,030			(10,809	)		(96	)		—			4,125
Income/(loss) before income taxes		(28,806	)		125,009			5,635			—			101,838
Income tax (provision)/benefit		10,086			(46,782	)		(2,367	)		—			(39,063	)
Equity in net income of subsidiaries		82,696			3,453			—			(86,149	)		—
Income from continuing operations		63,976			81,680			3,268			(86,149	)		62,775
Discontinued Operations		—			1,201			—			—			1,201
Net income	$	63,976		$	82,881		$	3,268		$	(86,149	)	$	63,976

				Guarantor			Non-Guarantor			Consolidating
For the year ended December 31, 2006	Parent			Subsidiaries			Subsidiaries			Adjustments			Consolidated
Continuing Operations
Net sales and service revenues	$	—		$	996,714		$	21,873		$	—		$	1,018,587
Cost of services provided and goods sold		—			719,074			11,049			—			730,123
Selling, general and administrative expenses		11,239			144,276			5,668			—			161,183
Depreciation		479			15,710			586			—			16,775
Amortization		1,267			3,985			3			—			5,255
Other operating expenses — net		—			272			—			—			272
Total costs and expenses		12,985			883,317			17,306			—			913,608
Income/(loss) from operations		(12,985	)		113,397			4,567			—			104,979
Interest expense		(16,909	)		(541	)		(18	)		—			(17,468	)
Loss on extinguishment of debt		(430	)		—			—			—			(430	)
Investment impairment charge		(1,445	)		—			—			—			(1,445	)
Other income — net		21,742			(17,107	)		13			—			4,648
Income/(loss) before income taxes		(10,027	)		95,749			4,562			—			90,284
Income tax (provision)/benefit		3,818			(34,491	)		(1,889	)		—			(32,562	)
Equity in net income of subsidiaries		59,059			2,673			—			(61,732	)		—
Income from continuing operations		52,850			63,931			2,673			(61,732	)		57,722
Discontinued Operations		(2,199	)		(4,872	)		—			—			(7,071	)
Net income	$	50,651		$	59,059		$	2,673		$	(61,732	)	$	50,651

32

Chemed Corporation and Subsidiary Companies

				Guarantor			Non-Guarantor			Consolidating
For the year ended December 31, 2005	Parent			Subsidiaries			Subsidiaries			Adjustments			Consolidated
Continuing Operations
Net sales and service revenues	$	—		$	896,085		$	19,885		$	—		$	915,970
Cost of services provided and goods sold		—			634,670			9,806			—			644,476
Selling, general and administrative expenses		13,132			138,828			5,302			—			157,262
Depreciation		442			15,189			519			—			16,150
Amortization		886			4,027			9			—			4,922
Other (income)/expenses — net		(959	)		17,350			—			—			16,391
Total costs and expenses		13,501			810,064			15,636			—			839,201
Income/(loss) from operations		(13,501	)		86,021			4,249			—			76,769
Interest expense		(20,548	)		(695	)		(21	)		—			(21,264	)
Loss on extinguishment of debt		(3,971	)		—			—			—			(3,971	)
Other income — net		22,362			(19,224	)		(16	)		—			3,122
Income/(loss) before income taxes		(15,658	)		66,102			4,212			—			54,656
Income tax (provision)/benefit		6,935			(23,259	)		(2,104	)		—			(18,428	)
Equity in net income of subsidiaries		42,936			2,108			—			(45,044	)		—
Income from continuing operations		34,213			44,951			2,108			(45,044	)		36,228
Discontinued Operations		1,604			(2,015	)		—			—			(411	)
Net income	$	35,817		$	42,936		$	2,108		$	(45,044	)	$	35,817

Condensed Consolidating Statement of Cash Flow

				Guarantor			Non-Guarantor
For the year ended December 31, 2007	Parent			Subsidiaries			Subsidiaries			Consolidated
Cash Flow from Operating Activities:
Net cash provided by operating activities	$	93		$	97,008		$	2,483		$	99,584
Cash Flow from Investing Activities:
Capital expenditures		(193	)		(25,674	)		(773	)		(26,640	)
Business combinations, net of cash acquired		—			(1,079	)		—			(1,079	)
Net proceeds/(payments) from sale of discontinued operations		2,502			(7,904	)		—			(5,402	)
Proceeds from sale of property and equipment		2,963			116			25			3,104
Other uses — net		(919	)		(751	)		(31	)		(1,701	)
Net cash provided/(used) by investing activities		4,353			(35,292	)		(779	)		(31,718	)
Cash Flow from Financing Activities:
Change in cash overdrafts payable		7			(926	)		—			(919	)
Change in intercompany accounts		66,095			(62,296	)		(3,799	)		—
Dividends (paid)/received to/from shareholders		(5,888	)		1,446			(1,446	)		(5,888	)
Purchases of treasury stock		(131,704	)		—			—			(131,704	)
Proceeds from exercise of stock options		2,467			—			—			2,467
Realized excess tax benefit on share based compensation		3,091			—			—			3,091
Purchase of note hedges		(55,100	)		—			—			(55,100	)
Proceeds from issuance of warrants		27,614			—			—			27,614
Proceeds from issuance of long-term debt		300,000			—			—			300,000
Debt issuance costs		(6,949	)		—			—			(6,949	)
Repayment of long-term debt		(225,500	)		(209	)		—			(225,709	)
Other sources and uses — net		40			(1	)		906			945
Net cash provided/(used) by financing activities		(25,827	)		(61,986	)		(4,339	)		(92,152	)
Net decrease in cash and cash equivalents		(21,381	)		(270	)		(2,635	)		(24,286	)
Cash and cash equivalents at beginning of year		25,258			(1,314	)		5,330			29,274
Cash and cash equivalents at end of period	$	3,877		$	(1,584	)	$	2,695		$	4,988

33

Chemed Corporation and Subsidiary Companies

				Guarantor			Non-Guarantor
For the year ended December 31, 2006	Parent			Subsidiaries			Subsidiaries			Consolidated
Cash Flow from Operating Activities:
Net cash provided by operating activities	$	6,326		$	88,434		$	3,829		$	98,589
Cash Flow from Investing Activities:
Capital expenditures		(138	)		(21,073	)		(776	)		(21,987	)
Business combinations, net of cash acquired		—			(4,145	)		—			(4,145	)
Net payments from sale of discontinued operations		(922	)		—			—			(922	)
Proceeds from sale of property and equipment		43			271			33			347
Investing activities of discontinued operations		—			(260	)		—			(260	)
Other sources and uses — net		(781	)		16			—			(765	)
Net cash used by investing activities		(1,798	)		(25,191	)		(743	)		(27,732	)
Cash Flow from Financing Activities:
Increase/(decrease) in cash overdrafts payable		(489	)		3,060			—			2,571
Change in intercompany accounts		67,502			(66,065	)		(1,437	)		—
Dividends paid to shareholders		(6,322	)		—			—			(6,322	)
Purchases of treasury stock		(19,885	)		—			—			(19,885	)
Proceeds from exercise of stock options		3,861			—			—			3,861
Excess tax benefit on share-based compensation		5,600			—			—			5,600
Debt issuance costs		(154	)		—			—			(154	)
Repayment of long-term debt		(84,363	)		(200	)		—			(84,563	)
Financing activities of discontinued operations		109			67			—			176
Net cash used by financing activities		(34,141	)		(63,138	)		(1,437	)		(98,716	)
Net increase/(decrease) in cash and cash equivalents		(29,613	)		105			1,649			(27,859	)
Cash and cash equivalents at beginning of year		54,871			(1,419	)		3,681			57,133
Cash and cash equivalents at end of year	$	25,258		$	(1,314	)	$	5,330		$	29,274

				Guarantor			Non-Guarantor
For the year ended December 31, 2005	Parent			Subsidiaries			Subsidiaries			Consolidated
Cash Flow from Operating Activities:
Net cash provided by operating activities	$	16,337		$	59,702		$	3,974		$	80,013
Cash Flow from Investing Activities:
Capital expenditures		(443	)		(24,588	)		(703	)		(25,734	)
Business combinations, net of cash acquired		—			(6,165	)		—			(6,165	)
Net payments from sale of discontinued operations		(9,367	)		—			—			(9,367	)
Proceeds from sale of property and equipment		1			153			3			157
Investing activities of discontinued operations		—			(239	)		—			(239	)
Other uses — net		(379	)		(15	)		—			(394	)
Net cash used by investing activities		(10,188	)		(30,854	)		(700	)		(41,742	)
Cash Flow from Financing Activities:
Increase in cash overdrafts payable		963			5,789			—			6,752
Change in intercompany accounts		45,051			(42,322	)		(2,729	)		—
Dividends paid to shareholders		(6,172	)		—			—			(6,172	)
Purchases of treasury stock		(7,401	)		—			—			(7,401	)
Proceeds from exercise of stock options		12,327			—			—			12,327
Proceeds from issuance of long-term debt		85,000			—			—			85,000
Debt issuance costs		(1,755	)		—			—			(1,755	)
Repayment of long-term debt		(141,125	)		(467	)		—			(141,592	)
Other sources — net		34			221			—			255
Net cash used by financing activities		(13,078	)		(36,779	)		(2,729	)		(52,586	)
Net increase/(decrease) in cash and cash equivalents		(6,929	)		(7,931	)		545			(14,315	)
Cash and cash equivalents at beginning of year		61,800			6,512			3,136			71,448
Cash and cash equivalents at end of period	$	54,871		$	(1,419	)	$	3,681		$	57,133

34

UNAUDITED SUMMARY OF QUARTERLY RESULTS

Chemed Corporation and Subsidiary Companies
(in thousands, except per share and footnote data)

	First			Second			Third			Fourth			Total
For the Year Ended December 31, 2007	Quarter			Quarter			Quarter			Quarter			Year
Continuing Operations
Total service revenues and sales	$	270,439		$	271,387		$	272,503		$	285,729		$	1,100,058
Gross profit	$	82,192		$	82,671		$	79,621		$	88,508		$	332,992
Income from operations	$	29,230		$	30,325		$	30,583		$	32,617		$	122,755
Interest expense		(3,742	)		(3,400	)		(2,515	)		(1,587	)		(11,244	)
Loss on extinguishment of debt		—			(13,715	)		(83	)		—			(13,798	)
Other income—net		869			2,188			11			1,057			4,125
Income before income taxes		26,357			15,398			27,996			32,087			101,838
Income taxes		(10,136	)		(5,965	)		(11,080	)		(11,882	)		(39,063	)
Income from continuing operations (a)		16,221			9,433			16,916			20,205			62,775
Discontinued Operations		—			—			1,201			—			1,201
Net Income (a)	$	16,221		$	9,433		$	18,117		$	20,205		$	63,976
Earnings Per Share (a)
Income from continuing operations	$	0.63		$	0.38		$	0.71		$	0.84		$	2.56
Net income	$	0.63		$	0.38		$	0.76		$	0.84		$	2.61
Diluted Earnings Per Share (a)
Income from continuing operations	$	0.62		$	0.38		$	0.69		$	0.83		$	2.50
Net income	$	0.62		$	0.38		$	0.74		$	0.83		$	2.55
Average number of shares outstanding
Earnings per share		25,716			24,506			23,933			23,959			24,520
Diluted earnings per share		26,162			25,080			24,466			24,460			25,077

(a) The following amounts are included in income from continuing operations during the respective quarter (in thousands):

	First			Second			Third			Fourth			Total
	Quarter			Quarter			Quarter			Quarter			Year
Pretax (cost)/benefit:
Long-term incentive plan payout	$	(5,447	)	$	(1,620	)	$	—		$	—		$	(7,067	)
Gain on sale of property		1,138			—			—			—			1,138
Stock option expense		(585	)		(897	)		(1,592	)		(1,591	)		(4,665	)
Expenses incurred in connection with the Office of Inspector General investigation		(66	)		(74	)		(48	)		(39	)		(227	)
Loss on extinguishment of debt		—			(13,715	)		(83	)		—			(13,798	)
Costs related to litigation settlement		—			—			—			(1,927	)		(1,927	)
Other		467			—			—			—			467
Total	$	(4,493	)	$	(16,306	)	$	(1,723	)	$	(3,557	)	$	(26,079	)
Aftertax (cost)/benefit:
Long-term incentive plan payout	$	(3,414	)	$	(1,013	)	$	—		$	—		$	(4,427	)
Gain on sale of property		724			—			—			—			724
Stock option expense		(371	)		(570	)		(1,011	)		(1,010	)		(2,962	)
Expenses incurred in connection with the Office of Inspector General investigation:		(41	)		(46	)		(30	)		(24	)		(141	)
Loss on extinguishment of debt		—			(8,726	)		(52	)		—			(8,778	)
Costs related to litigation settlement		—			—			—			(1,168	)		(1,168	)
Other		296			—			—			—			296
Total	$	(2,806	)	$	(10,355	)	$	(1,093	)	$	(2,202	)	$	(16,456	)

35

UNAUDITED SUMMARY OF QUARTERLY RESULTS

Chemed Corporation and Subsidiary Companies
(in thousands, except per share and footnote data)

	First			Second			Third			Fourth			Total
For the Year Ended December 31, 2006	Quarter			Quarter			Quarter			Quarter			Year
Continuing Operations
Total service revenues and sales	$	243,921		$	249,068		$	253,695		$	271,903		$	1,018,587
Gross profit	$	67,886		$	69,965		$	68,296		$	82,317		$	288,464
Income from operations	$	24,004		$	25,945		$	23,359		$	31,671		$	104,979
Interest expense		(5,345	)		(4,300	)		(4,081	)		(3,742	)		(17,468	)
Loss on extinguishment of debt		(430	)		—			—			—			(430	)
Loss from impairment of investment		—			—			(1,445	)		—			(1,445	)
Other income—net		1,495			524			715			1,914			4,648
Income before income taxes		19,724			22,169			18,548			29,843			90,284
Income taxes		(7,686	)		(8,619	)		(5,673	)		(10,584	)		(32,562	)
Income from continuing operations (a)		12,038			13,550			12,875			19,259			57,722
Discontinued Operations		177			(708	)		(4,914	)		(1,626	)		(7,071	)
Net Income (a)	$	12,215		$	12,842		$	7,961		$	17,633		$	50,651
Earnings Per Share (a)
Income from continuing operations	$	0.46		$	0.52		$	0.49		$	0.74		$	2.21
Net income	$	0.47		$	0.49		$	0.30		$	0.68		$	1.94
Diluted Earnings Per Share (a)
Income from continuing operations	$	0.45		$	0.50		$	0.48		$	0.73		$	2.16
Net income	$	0.46		$	0.48		$	0.30		$	0.67		$	1.90
Average number of shares outstanding
Earnings per share		26,044			26,201			26,190			26,030			26,118
Diluted earnings per share		26,723			26,846			26,633			26,411			26,669

(a) The following amounts are included in income from continuing operations during the respective quarter (in thousands):

	First			Second			Third			Fourth			Total
	Quarter			Quarter			Quarter			Quarter			Year
Pretax (cost)/benefit:
Loss on extinguishment of debt	$	(430	)	$	—		$	—		$	—		$	(430	)
Expenses incurred in connection with the Office of Inspector General investigation		(132	)		(342	)		(344	)		(250	)		(1,068	)
Stock option expense		—			(18	)		(597	)		(596	)		(1,211	)
Costs related to litigation settlements		—			—			(272	)		—			(272	)
Loss from impairment of investment		—			—			(1,445	)		—			(1,445	)
Other		—			—			—			467			467
Total	$	(562	)	$	(360	)	$	(2,658	)	$	(379	)	$	(3,959	)
Aftertax (cost)/benefit:
Loss on extinguishment of debt	$	(273	)	$	—		$	—		$	—		$	(273	)
Expenses incurred in connection with the Office of Inspector General investigation:		(82	)		(212	)		(213	)		(155	)		(662	)
Stock option expense		—			(12	)		(379	)		(378	)		(769	)
Costs related to litigation settlements		—			—			(169	)		—			(169	)
Loss from impairment of investment		—			—			(918	)		—			(918	)
Tax adjustments and settlements from prior year returns		—			—			1,791			324			2,115
Other		—			—			—			296			296
Total	$	(355	)	$	(224	)	$	112		$	87		$	(380	)

36

SELECTED FINANCIAL DATA

Chemed Corporation and Subsidiary Companies
(in thousands, except per share and footnote data, ratios, percentages and personnel)

	2007			2006			2005		2004(b)		2003
Summary of Operations
Continuing operations (a)
Service revenues and sales	$	1,100,058		$	1,018,587		$	915,970	$	734,877	$	260,776
Gross profit (excluding depreciation)		332,992			288,464			271,494		228,107		113,958
Depreciation		20,118			16,775			16,150		14,542		9,519
Amortization		5,270			5,255			4,922		3,779		302
Income from operations (b)		122,755			104,979			76,769		57,954		8,774
Income from continuing operations (c)		62,775			57,722			36,228		19,095		11,188
Net income/(loss) (c)		63,976			50,651			35,817		27,512		(3,435	)
Earnings/(loss) per share
Income from continuing operations	$	2.56		$	2.21		$	1.42	$	0.79	$	0.56
Net income/(loss)		2.61			1.94			1.40		1.14		(0.17	)
Average number of shares outstanding		24,520			26,118			25,552		24,120		19,848
Diluted earnings/(loss) per share
Income from continuing operations	$	2.50		$	2.16		$	1.38	$	0.78	$	0.56
Net income/(loss)		2.55			1.90			1.36		1.12		(0.17	)
Average number of shares outstanding		25,077			26,669			26,299		24,636		19,908
Cash dividends per share	$	0.24		$	0.24		$	0.24	$	0.24	$	0.24
Financial Position—Year-End
Cash and cash equivalents	$	4,988		$	29,274		$	57,133	$	71,448	$	50,688
Working capital/(deficit)		(13,427	)		(3,951	)		35,355		28,439		32,778
Current ratio		0.91			0.98			1.21		1.17		1.48
Properties and equipment, at cost less accumulated depreciation	$	74,513		$	70,140		$	65,155	$	55,796	$	31,440
Total assets		772,313			793,287			839,103		825,566		328,458
Long-term debt		214,669			150,331			234,058		279,510		25,931
Convertible junior subordinated debentures		—			—			—		—		14,126
Stockholders’ equity		364,349			421,361			384,175		332,092		192,693
Other Statistics—Continuing Operations
Capital expenditures	$	26,640		$	21,987		$	25,734	$	18,290	$	10,381
Number of employees		11,783			11,621			10,881		9,822		2,894

(a)	Continuing operations exclude VITAS of Arizona, discontinued in 2006; Service America, discontinued in 2004; and Patient Care, discontinued in 2002.
(b)	The financial results of VITAS are included in the consolidated results of the Company beginning on February 24, 2004, the date the Company acquired the remaining 63% of VITAS it did not own, bringing its ownership in VITAS to 100%.
(c)	The following amounts are included in income from continuing operations during the respective year (in thousands):

	2007			2006			2005			2004			2003
Aftertax benefit/(cost):
Loss on extinguishment of debt	$	(8,778	)	$	(273	)	$	(2,523	)	$	(2,030	)	$	—
Long-term incentive plan payout		(4,427	)		—			(3,434	)		(5,437	)		—
Stock option expense		(2,962	)		(769	)		(137	)		—			—
Costs related to litigation settlelments		(1,168	)		(169	)		(10,757	)		(1,897	)		—
Gain on sale of property		724			—			—			—			—
Expenses incurred in connection with the Office of Inspector General investigation		(141	)		(662	)		(397	)		—			—
Tax adjustments and settlements from prior-year returns		—			2,115			1,961			1,620			—
Loss on impairment of investment		—			(918	)		—			—			—
Adjustment to casualty insurance related to prior-periods experience		—			—			1,014			—			—
Adjustment of transaction-related expenses of the VITAS acquisition		—			—			959			(222	)		—
Equity in earnings/(loss) of VITAS		—			—			—			(4,105	)		922
Expenses related to debt registration		—			—			—			(727	)		—
Capital gains on sales of investments		—			—			—			—			3,351
Severance costs		—			—			—			—			(2,358	)
Other		296			296			—			—			—
Total	$	(16,456	)	$	(380	)	$	(13,314	)	$	(12,798	)	$	1,915

37

Chemed Corporation and Subsidiary Companies

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

EXECUTIVE SUMMARY

     We operate through our two wholly owned subsidiaries, VITAS Healthcare Corporation (“VITAS”) and Roto-Rooter Group, Inc. (“Roto-Rooter”). VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its team of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter is focused on providing plumbing and drain cleaning services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

     The following is a summary of the key operating results for the years ended December 31, 2007, 2006 and 2005 (in thousands except per share amounts):

	2007		2006		2005
Consolidated service revenues and sales	$	1,100,058	$	1,018,587	$	915,970
Consolidated income from continuing operations	$	62,775	$	57,722	$	36,228
Diluted EPS from continuing operations	$	2.50	$	2.16	$	1.38

2007 versus 2006

     The increase in consolidated service revenues and sales from 2006 to 2007 was driven by an 8% increase at both VITAS and Roto-Rooter. The increase at VITAS was the result of an increase in average daily census (“ADC”) of 6% and the annual Medicare price increase of 3% offset by changes in the mix of care. The increase at Roto-Rooter was mainly driven by price increases and job mix changes. Job count was essentially flat between years. Consolidated income from continuing operations and diluted EPS from continuing operations increased as a result of higher service revenues and sales, which allowed us to further leverage our current cost structure. The 2007 results were negatively impacted by pretax losses of $13.8 million ($8.8 million aftertax) related to our refinancing transactions discussed below.

2006 versus 2005

     The increase in consolidated service revenues and sales from 2005 to 2006 was driven by a 13% increase at VITAS and a 7% increase at Roto-Rooter. The increase at VITAS was the result of an increase in ADC of 10% and the annual Medicare price increase of 3.5% offset by changes in the mix of care. The increase at Roto-Rooter was mainly driven by a 1% increase in jobs, a 4.5% price increase and a shift in job mix. Consolidated income from continuing operations and diluted EPS from continuing operations increased in 2006 as a result of the higher service revenues and sales, which allowed us to further leverage our current cost structure. The 2005 results were negatively impacted by a $17.4 million pretax charge ($10.8 million aftertax) at VITAS for the settlement of a class action lawsuit.

Other Developments

     In the second quarter of 2007, we completed the following financing and capital transactions:

• Entered into a new senior secured credit facility due in 2012 which includes a $100 million term loan, a $175 million revolving credit facility and a $100 million expansion feature;

• Using the proceeds from the senior secured credit facility, we retired our $150 million, 8.75% Senior Notes at a price of 104.375% plus accrued but unpaid interest;

• Issued $200 million of 1.875% Senior Convertible Notes due in 2014;

• Using the proceeds from the Senior Convertible Notes, we repaid a portion of our revolving line of credit and we repurchased approximately 1.5 million shares of our outstanding capital stock.

     The effect of these transactions was to reduce our overall borrowing rate and to reduce the number of shares of capital stock outstanding. In connection with these transactions, we incurred a loss on extinguishment of debt of approximately $13.8 million related to the premium paid to retire our 8.75% Senior Notes and the write-off of deferred debt costs from the Senior Notes and replaced credit facility.

38

Chemed Corporation and Subsidiary Companies

LIQUIDITY AND CAPITAL RESOURCES

     Significant factors affecting our cash flows during 2007 and financial position at December 31, 2007, include the following:

• Our continuing operations generated cash of $99.6 million;

• We borrowed $300.0 million and repaid approximately $225.7 million in long-term debt;

• We repurchased our stock using cash of $131.7 million;

• We purchased hedges and sold warrants related to our convertible debt offering using net cash of $27.5 million; and

• We spent $26.6 million on capital expenditures.

     The ratio of total debt to total capital was 38.2% at December 31, 2007, compared with 26.3% at December 31, 2006. Our current ratio was 0.91 and 0.98 at December 31, 2007 and 2006, respectively. The change in these ratios from 2006 to 2007 relates mainly to our refinancing and repayment of long-term debt as well as our stock repurchase plan activity in 2007.

     Collectively, the 2007 Facility and the Notes require us to meet certain restrictive financial covenants, in addition to non-financial covenants, including maximum leverage ratios, minimum fixed charge coverage and consolidated net worth ratios, limits on operating leases and minimum asset value limits. We are in compliance with all financial and non-financial debt covenants as of December 31, 2007. We have issued $30.1 million in standby letters of credit as of December 31, 2007, mainly for insurance purposes. Issued letters of credit reduce our available credit under the revolving credit agreement. As of December 31, 2007, we have approximately $144.9 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility, excluding the expansion feature. We believe our cash flow from operating activities and our unused eligible lines of credit are sufficient to fund our business in the near term.

CASH FLOW

     Our cash flows for 2007, 2006 and 2005 are summarized as follows (in millions):

	For the Years Ended December 31,
	2007			2006			2005
Net cash provided by operating activities	$	99.6		$	98.6		$	80.0
Capital expenditures		(26.6	)		(22.0	)		(25.7	)
Operating cash excess after capital expenditures		73.0			76.6			54.3
Proceeds from issuance of long-term debt, net of costs		293.1			(0.2	)		83.2
Repayment of long-term debt		(225.7	)		(84.6	)		(141.6	)
Purchase of treasury stock		(131.7	)		(19.9	)		(7.4	)
Purchase of note hedge		(55.1	)		—			—
Proceeds from issuance of warrants		27.6			—			—
Dividends paid		(5.9	)		(6.3	)		(6.2	)
Net proceeds/(uses) from sale of discontinued operations		(5.4	)		(0.9	)		(9.4	)
Issuance of capital stock, net of costs		2.5			3.9			12.3
Business combinations		(1.1	)		(4.1	)		(6.2	)
Other—net		4.4			7.6			6.7
Decrease in cash and cash equivalents	$	(24.3	)	$	(27.9	)	$	(14.3	)

COMMITMENTS AND CONTINGENCIES

     In connection with the sale of DuBois Chemicals, Inc. (“DuBois”) in 1991, we provided allowances and accruals relating to several long-term costs, including income tax matters, lease commitments and environmental costs. Also, in conjunction with the sales of The Omnia Group (“Omnia”) and National Sanitary Supply Company in 1997, the sale of Cadre Computer Resources, Inc. (“Cadre Computer”) in 2001 and the sale of Service America Network Inc. (“Service America”) in 2005, we provided long-term allowances and accruals relating to costs of severance arrangements, lease commitments and income tax matters. Additionally, we retained liability for Service America’s casualty insurance claims that were incurred prior to the disposal date. In connection with the sale of VITAS’ Phoenix operation in November 2006, we have accrued an estimate of our total exposure for the Medicare Cap through the date of sale. In the aggregate, we believe these allowances and accruals are adequate as of December 31, 2007. Based on reviews of our environmental-related liabilities under the DuBois sale agreement, we have estimated our remaining liability to be $1.7 million. As of December 31, 2007, we are

39

Chemed Corporation and Subsidiary Companies

contingently liable for additional cleanup and related costs up to a maximum of $14.9 million, for which no provision has been recorded in accordance with the applicable accounting guidance.

     On September 28, 2006, we announced a preliminary settlement in regard to litigation related to the 2002 divestiture of our Patient Care business segment. Prior to the settlement, we had a long-term receivable from Patient Care of $12.5 million. We also had current accounts receivable from Patient Care for the post-closing balance sheet valuation and for expenses paid by us after closing on Patient Care’s behalf of $3.4 million. We were in litigation with Patient Care over the collection of these current amounts and their allegations that our acquisition of VITAS violated a non-compete covenant in the sales agreement. We agreed to forgive $1.2 million of the current receivable related to the post-closing balance sheet valuation and convert the remaining amount into debt secured by a promissory note with the same terms as the $12.5 million long-term receivable. We incurred additional costs related to the settlement of $1.1 million for additional insurance and legal costs related to workers’ compensation claims incurred prior to the sale. The aftertax charge related to these amounts of $1.5 million has been recorded as discontinued operations in 2006.

     In December 2007, the parties amended the terms of the long-term notes receivable from Patient Care. We agreed to waive the prepayment penalty provisions in the notes provided that Patient Care paid $5 million of principal on or before December 31, 2007, and the remaining outstanding principal on or before March 31, 2008. On December 31, 2007, we received a principal payment of $5 million from Patient Care. Subsequent to year-end, we received principal payments of $5.7 million from Patient Care. We anticipate receiving the remaining principal amount outstanding on or before March 31, 2008.

     We also have a warrant to purchase 2% of Patient Care’s common stock that we recorded as a $1.4 million investment. As a result of financial information received in 2006, we determined that the value of the warrants was permanently impaired and recorded a pretax impairment charge of $1.4 million. This charge is included in income from continuing operations on the consolidated statement of income for the year ended December 31, 2006.

     Like other large California employers, our VITAS subsidiary faces allegations of purported class-wide wage and hour violations. It was party to a class action lawsuit filed in the Superior Court of California, Los Angeles County, in April of 2004 by Ann Marie Costa, Ana Jimenez, Mariea Ruteaya and Gracetta Wilson (“Costa”). This case alleged failure to pay overtime wages for hours worked “off the clock” on administrative tasks, including voicemail retrieval, time entry, travel to and from work, and pager response. This case also alleged VITAS failed to provide meal and break periods to a purported class of California nurses, home health aides and licensed clinical social workers. The case also sought payment of penalties, interest, and Plaintiffs’ attorney fees. VITAS contested these allegations. During 2006, we reached a tentative settlement and on June 26, 2006, the court granted final approval of the settlement ($19.9 million).

     VITAS is party to a class action lawsuit filed in the Superior Court of California, Los Angeles County, in September 2006 by Bernadette Santos, Keith Knoche and Joyce White (“Santos”). This case, filed by the Costa case Plaintiffs’ counsel, makes similar allegations of failure to pay overtime and failure to provide meal and rest periods to a purported class of California admissions nurses, chaplains and sales representatives. The case likewise seeks payment of penalties, interest and Plaintiffs’ attorney fees. VITAS contests these allegations. The lawsuit is in its early stage and we are unable to estimate our potential liability, if any, with respect to these allegations.

     In April 2007, our Roto-Rooter subsidiary was named in a class action lawsuit filed in San Mateo Superior Court by Stanley Ita (“Ita”) alleging class-wide wage and hour violations at one California branch. This suit alleges failure to provide meal and break periods, credit for work time beginning from the first call to dispatch rather than arrival at first assignment and improper calculations of work time and overtime. The case sought payment of penalties, interest and Plaintiffs’ attorney fees. After the suit was filed, we offered a settlement to the members of the class and paid approximately $200,000. In January 2008, we agreed to a tentative settlement with the remaining members of the class for approximately $1.8 million. The tentative settlement is subject to court approval. The tentative settlement has been accrued in the accompanying financial statements as of and for the year ended December 31, 2007.

     In April 2005, the Office of Inspector General (“OIG”) for the Department of Health and Human Services served VITAS with civil subpoenas relating to VITAS’ alleged failure to appropriately bill Medicare and Medicaid for hospice services. As part of this investigation, the OIG selected medical records for 320 past and current patients from VITAS’ three largest programs for review. It also sought policies and procedures dating back to 1998 covering admissions, certifications, recertifications and discharges. During the third quarter of 2005 and again in May 2006, the OIG requested additional information from us. The Court dismissed a related qui tam complaint filed in U.S. District Court for the Southern District of Florida with prejudice in July 2007. The plaintiffs are appealing this dismissal. The government continues to investigate the complaint’s allegations. Pretax expenses related to complying with OIG requests have been immaterial in 2007. We

40

Chemed Corporation and Subsidiary Companies

incurred pretax expense related to complying with OIG requests and defending the litigation of $1.1 million and $637,000 for the years ended December 31, 2006 and 2005, respectively.

     Regardless of outcome, defense of litigation and complying with government investigations adversely affects us through defense costs, diversion of our time and related publicity. In the normal course of business, we are a party to various claims and legal proceedings. We record a reserve for these matters when an adverse outcome is probable and the amount of the potential liability is reasonably estimable.

CONTRACTUAL OBLIGATIONS

     The table below summarizes our debt and contractual obligations as of December 31, 2007 (in thousands):

			Less than						After
	Total		1 year		1-3 Years		4 -5 Years		5 Years
Long-term debt obligations	$	224,831	$	10,162	$	14,669	$	—	$	200,000
Interest obligation on long-term debt (a)		23,906		3,750		7,500		7,500		5,156
Operating lease obligations		54,635		15,010		22,089		11,111		6,425
Severance obligations		508		253		255		—		—
Liabilities related to uncertain tax positions.		1,169		270		539		360		—
Obligations of discontinued operations		2,516		1,345		1,171		—		—
Purchase obligations (b)		48,111		48,111		—		—		—
Other current obligations (c )		40,072		40,072		—		—		—
Other long-term obligations (d)		32,334		—		1,592		1,593		29,149
Total contractual cash obligations	$	428,082	$	118,973	$	47,815	$	20,564	$	240,730

(a)	Our interest obligation on long-term debt includes interest on fixed rate debt only.
(b)	Purchase obligations primarily consist of accounts payable at December 31, 2007.
(c)	Other current obligations consist of accrued salaries and wages at December 31, 2007.
(d)	Other long-term obligations comprise largely pension and excess benefit obligations.

RESULTS OF OPERATIONS

2007 Versus 2006 – Consolidated Results

     Set forth below are the year-to-year changes in the components of the statement of operations relating to continuing operations for 2007 versus 2006 (in thousands, except percentages):

	Increase/(Decrease)
	Amount			Percent
Service revenues and sales
VITAS	$	56,334			8	%
Roto-Rooter		25,137			8
Total		81,471			8
Cost of services provided and goods sold		36,943			5
Selling, general and administrative expenses		22,877			14
Depreciation		3,343			20
Amortization		15			0
Other expenses		517			190
Income from operations		17,776			17
Interest expense		6,224			(36	)
Loss on extinguishment of debt		(13,368	)		3,109
Loss from impairment of investment		1,445			(100	)
Other income —net		(523	)		(11	)
Income before income taxes		11,554			13
Income taxes		(6,501	)		20
Income from continuing operations	$	5,053			9

41

Chemed Corporation and Subsidiary Companies

     Our service revenues and sales for the year ended December 31, 2007, increased $81.5 million, or 8%, versus revenues for the year ended December 31, 2006. The VITAS segment accounted for $56.4 million of this increase and Roto-Rooter accounted for the remaining $25.1 million of the increase.

     The increase in VITAS’ revenues for 2007 versus 2006 is attributable to the following (dollars in thousands):

	Amount			Percent
Routine homecare	$	54,860			11	%
Continuous care		(5,295	)		(4	)
General inpatient		3,113			3
Medicare Cap		3,656			(94	)
Total revenues	$	56,334			8

     The revenue increase for VITAS includes the annual increase in the Medicare reimbursement rate of approximately 3% to 4%. In addition, the ADC for routine homecare and general inpatient increased 7.3% and 1.5%, respectively, from 2006. ADC for continuous care decreased 7.6% from 2006. ADC is a key measure we use to monitor volume growth in our hospice programs. Changes in total program admissions and average length of stay for our patients are the main drivers of changes in ADC. Additionally, we had a $3.7 million favorable comparison from 2006 related to reductions in revenue for the Medicare Cap. We recorded a reduction in revenue for Medicare Cap in 2007 of $242,000 compared to $3.9 million in 2006. The improvement is a result of improved admissions and consolidation of certain provider numbers within key programs. The 2007 revenue reduction is related to retroactive billings from prior periods for patients who transferred between hospice providers. No Medicare Cap liability for the 2007 or 2008 measurement periods have been recorded as of December 31, 2007.

     The increase in Roto-Rooter’s service revenues and sales for 2007 versus 2006 is attributable to the following (in thousands):

	Amount		Percent
Plumbing	$	13,973		11	%
Sewer and drain cleaning		6,353		4
Other		4,811		11
Total revenues	$	25,137		8

     Plumbing revenues for 2007 increased from 2006 due to a 4% increase in the average price per job and a 7% increase in the number of jobs performed. Sewer and drain cleaning revenues for 2007 increased from 2006 due to a 7% increase in the average price per job offset by a 3% decrease in the number of jobs performed. The increase in other revenues is attributable primarily to increases in independent contractor operations.

     The consolidated gross margin was 30.3% in 2007 versus 28.3% in 2006. On a segment basis, VITAS’ gross margin was 22.4% in 2007 and 20.3% in 2006. The Medicare Cap accounts for approximately 0.5% of the increase in VITAS’ gross margin. Approximately 0.5% of the improvement in gross margin relates to certain expenses that were historically cost of services but were centralized in 2007 and are now included in selling, general and administrative (“SG&A”) expenses. The remaining improvement relates to better utilization of our labor in 2007. In 2006, we experienced lower gross margins due to excess patient care capacity. Roto-Rooter’s gross margin was 47.6% in 2007 and 45.9% in 2006. The improvement in Roto-Rooter’s gross margin is the result of price increases noted above coupled with continued improvement in retention of service technicians, which enhances overall productivity of the workforce and reduces our workers’ compensation costs.

     Selling, general and administrative expenses (“SG&A”) for 2007 increased $22.9 million (14%). The increase is attributable to an increase in LTIP costs of $7.1 million, stock option expense of $3.5 million and advertising costs of $2.7 million. Additionally, $3.8 million of the increase relates to the centralization of certain activities at our VITAS subsidiary which were previously at the program level and classified as cost of services prior to 2007. The remaining increase in SG&A is the result of typical cost of living increases for salaries and benefits plus increases in certain selling expenses which vary based on changes in revenue.

42

Chemed Corporation and Subsidiary Companies

     Depreciation expense increased $3.3 million (20%) in 2007 compared to 2006 due to increased depreciation on computer hardware and leasehold improvements mainly at our VITAS subsidiary. Other expenses increased $517,000 due to the impact of the settlement of a class action lawsuit at Roto-Rooter offset by the gain on sale of Roto-Rooter’s Florida call center facility.

     Interest expense decreased $6.2 million (36%) from 2006 to 2007 mainly due to the refinancing in May 2007 and the subsequent repayment of long-term debt throughout the remainder of 2007. In conjunction with our May 2007 refinancing transactions, we recorded a loss on extinguishment of debt of $13.8 million. In the third quarter of 2006, we recorded a $1.4 million impairment charge related to our investment in the warrants of Patient Care as discussed in the commitments and contingencies section above.

     Our effective income tax rate was 38.4% in 2007 versus 36.1% in 2006. The increase in our effective tax rate relates to the $2.1 million tax adjustment required upon expiration of certain statutes in 2006. As a result of the adoption of FIN 48 on January 1, 2007, no such tax adjustments were necessary in 2007.

     Income from continuing operations increased $5.1 million (9%) from 2006 to 2007. Income from continuing operations for both periods include the following aftertax adjustments that increased/(reduced) after tax earnings (in thousands):

	2007			2006
VITAS
Costs associated with the OIG investigation	$	(141	)	$	(662	)
Costs of class action litigation		—			(169	)
Roto-Rooter
Costs related to class action litigation		(1,168	)		—
Gain on sale of property		724			—
Tax adjustments required upon expiration of statutes		—			1,251
Corporate
Loss on extinguishment of debt		(8,778	)		(273	)
Long-term incentive compensation		(4,427	)		—
Stock option expense		(2,962	)		(769	)
Tax adjustments required upon expiration of statutes		—			864
Impairment of Patient Care warrants		—			(918	)
Other		296			296
Total	$	(16,456	)	$	(380	)

     Income/(loss) from discontinued operations for 2007, 2006 and 2005 follows (in thousands):

	For the Years Ended December 31,
	2007		2006			2005
VITAS Phoenix	$	1,201	$	(4,872	)	$	1,477
Service America		—		(32	)		(1,813	)
Adjustment to accruals of operations discontinued in prior years		—		(2,167	)		(75	)
Income/(loss) from discontinued operations	$	1,201	$	(7,071	)	$	(411	)

     In September 2006, our Board of Directors approved and we announced our intention to exit the hospice market in Phoenix, Arizona. As a result of our announcement, we performed interim impairment tests of our long-lived assets of the Phoenix operation as of September 30, 2006, in accordance with Statement of Financial Accounting Standards No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets.” An impairment charge of $2.4 million was recorded for the referral network intangible asset and fixed assets during the third quarter of 2006. The sale was completed in November 2006. The acquiring corporation purchased the substantial majority of assets of the Phoenix program for $2.5 million. In October 2007, we received notification from the Federal government’s fiscal intermediary regarding our Medicare Cap liabilities related to the 2006 measurement period. The notification revealed that we were over accrued at our discontinued Phoenix operation by $1.9 million. We have recorded the reversal of this over accrual and its related tax effects in

43

Chemed Corporation and Subsidiary Companies

discontinued operations during the year ended December 31, 2007. As of December 31, 2007, we have $500,000 accrued for potential retroactive billings related to the Medicare Cap for Phoenix.

2007 Versus 2006 – Segment Results

     The change in net income for 2007 versus 2006 is due to (in thousands, except percentages):

	Increase/(Decrease)
	Amount			Percent
VITAS	$	11,415			24	%
Roto-Rooter		6,397			20
Corporate		(12,759	)		55
Discontinued operations		8,272			(117	)
	$	13,325			26

2006 Versus 2005 – Consolidated Results

     Set forth below are the year-to-year changes in the components of the statement of operations relating to continuing operations for 2006 versus 2005 (in thousands, except percentages):

	Increase/(Decrease)
	Amount			Percent
Service revenues and sales
VITAS	$	80,459			13	%
Roto-Rooter		22,158			7
Total		102,617			11
Cost of services provided and goods sold		85,647			13
Selling, general and administrative expenses		3,921			2
Depreciation		625			4
Amortization		333			7
Other expenses		(16,119	)		(98	)
Income from operations		28,210			37
Interest expense		3,796			(18	)
Loss on impairment of investment		(1,445	)		—
Loss on extinguishment of debt		3,541			(89	)
Other income —net		1,526			49
Income before income taxes		35,628			65
Income taxes		(14,134	)		77
Income from continuing operations	$	21,494			59

     Our service revenues and sales for the year ended December 31, 2006, increased $102.6 million, or 11%, versus revenues for the year ended December 31, 2005. The VITAS segment accounted for $80.4 million of this increase and Roto-Rooter accounted for the remaining $22.2 million of the increase.

     The increase in VITAS’ revenues for 2006 versus 2005 is attributable to the following (dollars in thousands):

	Amount			Percent
Routine homecare	$	65,632			15	%
Continuous care		14,679			14
General inpatient		4,046			5
Medicare cap		(3,898	)		—
Total revenues	$	80,459			13

     The revenue increase for VITAS includes the annual increase in the Medicare reimbursement rate of approximately 3% to 4%. In addition, the Average Daily Census (“ADC”) for routine homecare, continuous care and general inpatient

44

Chemed Corporation and Subsidiary Companies

increased 10.7%, 8.2% and 1.0%, respectively, from 2005. ADC is a key measure we use to monitor volume growth in our hospice programs. Changes in total program admissions and average length of stay for our patients are the main drivers of changes in ADC. The increases discussed above were offset by a reduction in revenue of $3.9 million related to the Medicare Cap. The components of the pretax charges are as follows (in thousands):

			All
	Phoenix		Other		Total
2007 measurement period	$	—	$	470	$	470
2006 measurement period		7,260		2,903		10,163
2005 measurement period		671		525		1,196
Total	$	7,931	$	3,898	$	11,829

     The amounts related to the Phoenix program are included in discontinued operations. Charges for the 2005 measurement period relate to prior-year billing limitations resulting from the fiscal intermediary reallocating admissions for deceased Medicare patients who received hospice care from multiple providers. The amounts for the 2006 and 2007 measurement periods are estimates made by management based upon Medicare admissions and Medicare revenue in each program.

     The increase in Roto-Rooter’s service revenues and sales for 2006 versus 2005 is attributable to the following (in thousands):

	Amount		Percent
Plumbing	$	10,265		9	%
Sewer and drain cleaning		10,420		8
Other		1,473		3
Total revenues	$	22,158		7

     Plumbing revenues for 2006 increased from 2005 due to a 7% increase in the average price per job and a 1% increase in the number of jobs performed. The increase in the average price per job reflects a combination of price increases coupled with our focus on larger commercial jobs. Our average price for a commercial plumbing job is approximately 36% higher than the average price for a residential plumbing job. Sewer and drain cleaning revenues for 2006 increased from 2005 due to a 7% increase in the average price per job and a 1% increase in the number of jobs performed. The increase in the average price per job reflects a combination of price increases coupled with our focus on larger commercial jobs. Our average price for a commercial sewer and drain-cleaning job is approximately 37% higher than the average price for a residential sewer and drain-cleaning job. The increase in other revenues is attributable primarily to increases in independent contractor operations.

     The consolidated gross margin was 28.3% in 2006 versus 29.6% in 2005. On a segment basis, VITAS’ gross margin was 20.3% in 2006 and 21.7% in 2005. The Medicare Cap accounts for approximately 0.6% of the decrease in VITAS’ gross margin. The remaining difference is attributable to increased labor costs. Given the historic difficulty in hiring and retaining qualified healthcare professionals, management continued to build manpower in expectation of future increases in admissions and ADC. Additionally, some of our fastest growing hospice programs are located in areas with a high cost of living, which increases our overall average labor cost per patient day served. Roto-Rooter’s gross margin was 45.9% in 2006 and 46.2% in 2005.

     Selling, general and administrative expenses (“SG&A”) for 2006 increased $3.9 million (2.5%) as summarized below (in thousands):

Increase in selling expenses	$	2,007
Increase in general and administrative expenses		1,914
Total increase	$	3,921

     The increase in selling expenses is mainly attributable to an increase in advertising costs at Roto-Rooter. The increase in general and administrative expenses is caused mainly by salary increases and the impact of expensing stock options beginning in 2006 ($1.2 million) offset by a decrease in LTIP expenses of $5.5 million.

45

Chemed Corporation and Subsidiary Companies

     Other expenses decreased $16.1 million mainly due to the impact of the settlement of a class action lawsuit at VITAS in 2005.

     Income from operations for 2006 increased $28.2 million (37%) versus 2005 as summarized below (in thousands):

Increase in gross margin	$	16,970
Increase in SG&A expenses, depreciation, and amortization		(4,879	)
Cost in 2005 of settling VITAS’ class action litigation		17,350
All other		(1,231	)
Total increase	$	28,210

     Interest expense decreased $3.8 million (18%) from 2005 to 2006 mainly due to the repayment of approximately $85 million in long-term debt in March 2006. In the third quarter of 2006, we recorded a $1.4 million impairment charge related to our investment in the warrants of Patient Care as further discussed in the commitments and contingencies section above.

     Our effective income tax rate was 36.1% in 2006 versus 33.7% in 2005. The increase in our effective tax rate relates to the tax adjustments required upon expiration of certain statutes, of $2.1 million in 2006 and $2.0 million in 2005. While the dollar amounts are consistent between years, the 2005 amount is a larger percentage of pretax income and thus has a larger impact on reducing the overall rate for 2005.

     Income from continuing operations increased $21.5 million (59%) from 2005 to 2006. Income from continuing operations for both periods include the following after tax adjustments that increased/(reduced) after tax earnings (in thousands):

	2006			2005
VITAS
Costs associated with the OIG investigation	$	(662	)	$	(397	)
Costs of class action litigation		(169	)		(10,757	)
Roto-Rooter
Tax adjustments required upon expiration of statutes		1,251			1,126
Favorable adjustment to casualty insurance		—			1,014
Corporate
Stock option expense		(769	)		(137	)
Long-term incentive compensation		—			(3,434	)
VITAS transaction expense adjustments		—			959
Impairment of Patient Care warrants		(918	)		—
Tax adjustments required upon expiration of statutes		864			835
Loss on extinguishment of debt		(273	)		(2,523	)
Other		296			—
Total	$	(380	)	$	(13,314	)

     Income/(loss) from discontinued operations for 2006, 2005 and 2004 follows (in thousands):

	For the Years Ended December 31,
	2006			2005			2004
VITAS Phoenix	$	(4,872	)	$	1,477		$	91
Service America		(32	)		(1,813	)		8,559
Adjustment to accruals of operations discontinued in prior years		(2,167	)		(75	)		(233	)
Income/(loss) from discontinued operations	$	(7,071	)	$	(411	)	$	8,417

     The disposal of Service America was completed in May 2005. The loss on disposal of Service America in 2005 arises from the finalization of asset and liability values and related tax benefits resulting from the consummation of the sale transaction. For 2004, the gain for Service America includes an estimated tax benefit on the disposal of approximately $14.2 million, primarily due to the recognition of non-deductible goodwill impairment losses in prior years.

46

Chemed Corporation and Subsidiary Companies

     The adjustments to accruals related to operations discontinued in prior years primarily include the Patient Care settlement in 2006, favorable adjustments to accruals for note receivable losses on the sale of Cadre Computer (discontinued in 2001) and unfavorable adjustments to accruals related to the sale of DuBois in 1991. Adjustments to the DuBois accruals relate to environmental liabilities we retained upon the sale of DuBois in 1991. We believe amounts accrued are reasonable under the circumstances, but due to the nature of the liabilities, we could be required to increase the accrual in future years to cover additional charges.

2006 Versus 2005 – Segment Results

     The change in net income for 2006 versus 2005 is due to (dollars in thousands):

	Increase/(Decrease)
	Amount			Percent
VITAS	$	14,913			45	%
Roto-Rooter		4,828			17
Corporate		1,753			7
Discontinued operations		(6,660	)		(1,620	)
Total increase	$	14,834			41

CRITICAL ACCOUNTING POLICIES

Revenue Recognition

     For both the Roto-Rooter and VITAS segments, service revenues and sales are recognized when the earnings process has been completed. Generally, this occurs when services are provided or products are delivered. Sales of Roto-Rooter products, including drain cleaning machines and drain cleaning solution, comprise less than 2% of our total service revenues and sales for each of the three years in the period ended December 31, 2007.

     VITAS recognizes revenue at the estimated net realizable amount due from third-party payers, which are primarily Medicare and Medicaid. Payers may deny payment for services in whole or in part on the basis that such services are not eligible for coverage and do not qualify for reimbursement. We estimate denials each period and make adequate provision in the financial statements. The estimate of denials is based on historical trends and known circumstances and generally does not vary materially from period to period on an aggregate basis.

     VITAS is subject to certain limitations on Medicare payments for services. Specifically, if the number of inpatient care days any hospice program provides to Medicare beneficiaries exceeds 20% of the total days of hospice care such program provides to all patients for an annual period beginning September 28, the days in excess of the 20% figure may be reimbursed only at the routine homecare rate. We have never had a program reach the inpatient cap. None of our hospice programs are expected to be within 15% of the inpatient cap for the 2007 measurement period while the majority of our programs have expected cushion in excess of 75% of the inpatient cap. Due to the significant cushion at each program, we do not anticipate it to be reasonably likely that any program will be subject to the inpatient cap in the foreseeable future.

     VITAS is also subject to a Medicare annual per-beneficiary Cap. Compliance with the Medicare Cap is measured by comparing the total Medicare payments received under a Medicare provider number with respect to services provided to all Medicare hospice care beneficiaries in the program or programs covered by that Medicare provider number between November 1 of each year and October 31 of the following year with the product of the per-beneficiary Cap amount and the number of Medicare beneficiaries electing hospice care for the first time from that hospice program or programs during the relevant period.

     We actively monitor each of our hospice programs, by provider number, as to their specific admissions, discharge rate and median length of stay data in an attempt to determine whether they are likely to exceed the Medicare Cap. Should we determine that a provider number is likely to exceed the Medicare Cap based on projected trends, we attempt to institute corrective action to influence the patient mix or to increase patient admissions. However, should we project our corrective action will not prevent that program from exceeding its Medicare Cap, we estimate the amount of revenue recognized during the period that will require repayment to the Federal government under the Medicare Cap and record that amount as a reduction in service revenue.

     Our estimate of the Medicare Cap liability is particularly sensitive to allocations made by our fiscal intermediary relative to patient transfers between hospices. We are allocated a percentage of the Medicare Cap based on the total days a patient spent in hospice care. The allocation for patient transfers cannot be determined until a patient dies. As the number of

47

Chemed Corporation and Subsidiary Companies

days a patient spends in hospice is based on a future event, this allocation process may take several years. Therefore, we use only first time Medicare admissions in our estimate of the Medicare Cap billing limitation. This method assumes that credit received for patients who transfer into our program will be offset by credit lost from patients who transfer out of our program. If the actual relationship of transfers in and transfers out for a given measurement period proves to be different for any program at or near a billing limitation, our estimate of the liability would increase or decrease on a dollar-for-dollar basis. While our method has historically been materially accurate, each program can vary during a given measurement period.

     Based on the methodology discussed above, we have not recorded a Medicare Cap liability for the 2007 or 2008 measurement period during the year ended December 31, 2007. Due to the variability caused by patient transfers, we have calculated the potential range of loss for all continuing programs to be between zero and $1.5 million for the year ended December 31, 2007.

Insurance Accruals

     For the Roto-Rooter segment and Chemed’s Corporate Office, we self-insure for all casualty insurance claims (workers’ compensation, auto liability and general liability). As a result, we closely monitor and frequently evaluate our historical claims experience to estimate the appropriate level of accrual for self-insured claims. Our third-party administrator (“TPA”) processes and reviews claims on a monthly basis. Currently, our exposure on any single claim is capped at $500,000. For most of the prior years, the caps for general liability and workers’ compensation were between $250,000 and $500,000 per claim. In developing our estimates, we accumulate historical claims data for the previous 10 years to calculate loss development factors (“LDF”) by insurance coverage type. LDFs are applied to known claims to estimate the ultimate potential liability for known and unknown claims for each open policy year. LDFs are updated annually. Because this methodology relies heavily on historical claims data, the key risk is whether the historical claims are an accurate predictor of future claims exposure. The risk also exists that certain claims have been incurred and not reported on a timely basis. To mitigate these risks, in conjunction with our TPA, we closely monitor claims to ensure timely accumulation of data and compare claims trends with the industry experience of our TPA.

     For the VITAS segment, we self-insure for workers’ compensation claims. Currently, VITAS’ exposure on any single claim is capped at $500,000. For VITAS’ self-insurance accruals for workers’ compensation, the valuation methods used are similar to those used internally for our other business units.

     Our casualty insurance liabilities are recorded gross before any estimated recovery for amounts exceeding our stop loss limits. Estimated recoveries from insurance carriers are recorded as accounts receivable. Claims experience related adjustments to our casualty and workers’ compensation accrual for the years ended December 31, 2007, 2006 and 2005 were net, pretax credits of $2.9 million, $2.1 million and $4.1 million, respectively.

     As an indication of the sensitivity of the accrued liability to reported claims, our analysis indicates that a 1% across-the-board increase or decrease in the amount of projected losses for all of our continuing operations would increase or decrease the accrued insurance liability at December 31, 2007, by $1.4 million or 3.9%. While the amount recorded represents our best estimate of the casualty and workers’ compensation insurance liability, we have calculated, based on historical claims experience, the actual loss could reasonably be expected to increase or decrease by approximately $2.3 million as of December 31, 2007.

Income Taxes

     Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amount of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in our opinion, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in laws and rates on the date of enactment.

     We are subject to income taxes in the Federal and most state jurisdictions. We are periodically audited by various taxing authorities. Significant judgment is required to determine our provision for income taxes. On January 1, 2007, we adopted FASB Interpretation No. 48 (FIN 48), “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement 109,” which prescribes a comprehensive model for how to recognize, measure, present and disclose in financial statements uncertain tax positions taken or expected to be taken on a tax return. Upon adoption of FIN 48, the financial statements reflect expected future tax consequences of such uncertain positions assuming the taxing authorities’ full knowledge of the position and all relevant facts.

48

Chemed Corporation and Subsidiary Companies

Goodwill and Intangible Assets

     Identifiable, definite-lived intangible assets arise from purchase business combinations and are amortized using either an accelerated method or the straight-line method over the estimated useful lives of the assets. The selection of an amortization method is based on which method best reflects the economic pattern of usage of the asset. The VITAS trade name is considered to have an indefinite life. Goodwill and the VITAS trade name are tested at least annually for impairment. The valuation of goodwill and the VITAS trade name is dependent upon many factors, some of which are market-driven and beyond our control. The valuation of goodwill and the VITAS trade name indicate that the fair value exceeds the carrying value at October 1, 2007.

Stock-based Compensation Plans

     Effective January 1, 2006, we adopted the provisions of Statement of Financial Accounting Standards No. 123, revised (“SFAS 123(R)”) which establishes accounting for stock-based compensation for employees. Under SFAS 123(R), stock-based compensation cost is measured at the grant date, based on the fair value of the award and recognized as expense over the employee’s requisite service period on a straight-line basis. We previously applied Accounting Principles Board Opinion No. 25 and provided the pro-forma disclosures required by Statement of Financial Accounting Standards No. 123. We elected to adopt the modified prospective transition method as provided by SFAS 123(R). Accordingly, we have not restated previously reported financial statement amounts. Other than certain reclassifications, there was no material impact on our financial position, results of operations or cash flows as a result of the adoption of SFAS 123(R).

     We estimate the fair value of stock options using the Black-Scholes valuation model, consistent with the provisions of SFAS 123(R), the Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 107 and our prior-period pro-forma disclosure of net income including stock-based compensation expense. We determine expected term, volatility, dividend yield and forfeiture rate based on our historical experience. We believe that historical experience is the best indicator of these factors.

RECENT ACCOUNTING STATEMENTS

     In December 2007, the FASB issued Statement No. 141(R) ”Business Combinations (revised 2007)” (“SFAS 141(R)”), which changes certain aspects of the accounting for business combinations. This Statement retains the fundamental requirements in Statement No. 141 that the purchase method of accounting be used for all business combinations and for an acquirer to be identified for each business combination. SFAS 141(R) modifies existing accounting guidance in the areas of deal and restructuring costs, acquired contingencies, contingent consideration, in-process research and development, accounting for subsequent tax adjustments and assessing the valuation date. This Statement applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. An entity may not apply it before that date. There will be no impact on our financial statements as a result of the adoption of SFAS 141(R), however our accounting for all business combinations after adoption will comply with the new standard.

     In December 2007, the FASB issued Statement No. 160 “Non-controlling Interests in Consolidated Financial Statements – an amendment of ARB No. 51” (“SFAS 160”), which requires ownership interests in subsidiaries held by others to be clearly identified, labeled and presented in the consolidated balance sheet within equity but separate from the parent company’s equity. SFAS 160 also affects the accounting requirements when the parent company either purchases a higher ownership interest or deconsolidates the equity investment. This Statement applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. An entity may not apply it before that date. We currently do not have noncontrolling interests in our consolidated financial statements.

     In February 2007, the FASB issued Statement No. 159 “The Fair Value Option for Financial Assets and Financial Liabilities” (“SFAS 159”), which permits an entity to measure certain financial assets and financial liabilities at fair value. Entities that elect the fair value option will report unrealized gains and losses in earnings at each reporting date. The fair value option may be elected on an instrument-by-instrument basis, with a few exceptions, as long as it is applied to the entire instrument. The fair value election is irrevocable unless a new election date occurs. SFAS 159 is effective as of the beginning of the first fiscal year that begins after November 15, 2007. There will be no impact on our financial condition and results of operations as a result of the adoption of SFAS 159.

     In September 2006, the FASB issued Statement No. 157 “Fair Value Measurements”(“SFAS 157”), which addresses how companies should measure fair value when they are required to use a fair value measure for recognition or disclosure purposes under generally accepted accounting principles (GAAP). It sets a common definition of fair value to be used throughout GAAP. The new standard is designed to make the measurement of fair value more consistent and comparable and improve disclosures about those measures. This statement is effective for financial statements issued for

49

Chemed Corporation and Subsidiary Companies

fiscal years beginning after November 15, 2007. There will be no impact on our financial condition and results of operations as a result of the adoption of SFAS 157. We are currently evaluating the impact SFAS 157 will have on our footnote disclosures.

50

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
OPERATING STATISTICS FOR VITAS SEGMENT
FOR THE YEARS ENDED DECEMBER, 2007 AND 2006
(unaudited)

	Three Months Ended December 31,						Years Ended December 31,
	2007			2006			2007			2006
OPERATING STATISTICS
Net revenue ($000)
Homecare	$	143,125		$	132,082		$	546,872		$	492,012
Inpatient		23,927			23,316			92,995			89,882
Continuous care		30,150			31,509			115,801			121,096
Total before Medicare Cap allowance	$	197,202		$	186,907		$	755,668		$	702,990
Medicare Cap allowance		—			(688	)		(242	)		(3,898	)
Total	$	197,202		$	186,219		$	755,426		$	699,092
Net revenue as a percent of total before Medicare Cap allowance
Homecare		72.6	%		70.6	%		72.4	%		70.0	%
Inpatient		12.1			12.5			12.3			12.8
Continuous care		15.3			16.9			15.3			17.2
Total before Medicare Cap allowance		100.0			100.0			100.0			100.0
Medicare Cap allowance		—			(0.4	)		—			(0.6	)
Total		100.0	%		99.6	%		100.0	%		99.4	%
Average daily census (“ADC”) (days)
Homecare		7,121			6,636			6,966			6,333
Nursing home		3,610			3,567			3,581			3,501
Routine homecare		10,731			10,203			10,547			9,834
Inpatient		417			411			417			411
Continuous care		512			560			513			555
Total		11,660			11,174			11,477			10,800
Total Admissions		13,594			13,291			54,798			52,736
Total Discharges		13,700			13,199			54,530			51,552
Average length of stay (days)		75.7			75.7			76.5			71.9
Median length of stay (days)		14.0			14.0			13.0			13.0
ADC by major diagnosis
Neurological		32.8	%		33.7	%		33.1	%		33.4	%
Cancer		20.4			19.7			20.1			20.2
Cardio		13.5			14.7			14.1			14.8
Respiratory		6.8			7.0			6.8			7.1
Other		26.5			24.9			25.9			24.5
Total		100.0	%		100.0	%		100.0	%		100.0	%
Admissions by major diagnosis
Neurological		18.5	%		19.8	%		18.5	%		19.8	%
Cancer		36.6			35.3			36.1			35.5
Cardio		11.9			12.7			12.6			13.1
Respiratory		7.3			7.2			7.5			7.3
Other		25.7			25.0			25.3			24.3
Total		100.0	%		100.0	%		100.0	%		100.0	%
Direct patient care margins
Routine homecare		51.6	%		49.7	%		51.1	%		49.0	%
Inpatient		18.8			19.4			18.4			20.0
Continuous care		17.6			17.0			18.0			18.2
Homecare margin drivers (dollars per patient day)
Labor costs	$	49.59		$	49.72		$	49.14		$	49.38
Drug costs		7.73			8.17			7.90			8.12
Home medical equipment		5.91			5.81			5.78			5.63
Medical supplies		2.49			2.28			2.25			2.17
Inpatient margin drivers (dollars per patient day)
Labor costs	$	272.46		$	261.55		$	265.47		$	259.25
Continuous care margin drivers (dollars per patient day)
Labor costs	$	506.72		$	486.46		$	486.90		$	468.13
Bad debt expense as a percent of revenues		1.0	%		1.0	%		0.9			0.9	%
Accounts receivable —days of revenue outstanding		43.4			38.7			N.A.			N.A.

51

Chemed Corporation and Subsidiary Companies

CORPORATE GOVERNANCE

     We submitted our Annual Certification of the Chief Executive Officer to the New York Stock Exchange (“NYSE”) regarding the NYSE corporate governance listing standards on May 24, 2007. We also filed our Certifications of the President and Chief Executive Officer, the Executive Vice President and Chief Financial Officer and the Vice President and Controller pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 as Exhibits 31.1, 31.2 and 31.3, respectively, to our Annual Report on Form 10-K for the year ended December 31, 2007.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 REGARDING FORWARD-LOOKING INFORMATION

     In addition to historical information, this report contains forward-looking statements and performance trends that are based upon assumptions subject to certain known and unknown risks, uncertainties, contingencies and other factors. Such forward-looking statements and trends include, but are not limited to, the impact of laws and regulations on our operations, our estimate of future effective income tax rates and the recoverability of deferred tax assets. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. Our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of our projections and other financial matters.

52